Anti-CCR8 antibodies

By developing antibodies targeting CCR8, blocking the interaction between CCR8 and CCL1, the immunosuppression problem caused by the increase of regulatory T cells in tumors was solved, and efficient depletion of Treg cells in tumors and the improvement of anti-tumor immunity was achieved.

CN118922444APending Publication Date: 2024-11-08QILU PUGET SOUND BIOTHERAPEUTICS CORP
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202380027553.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-10-17
Filing Date
2023-01-13
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The prior art is difficult to effectively selectively inhibit or kill regulatory T cells in tumors to restore or enhance anti-tumor immunity, resulting in poor immunotherapy.

Method used

An anti-C-C motif chemokine receptor 8 (CCR8) antibody was developed to target the interaction of CCR8 with its ligand CCL1, blocking regulatory T cells that inhibit CCR8 expression, thereby reducing intratumoral intratumoral The number of Treg cells enhances the anti-tumor immune response.

Benefits of technology

This antibody can efficiently block CCL1-mediated chemotaxis, specifically deplete intratumoral T cells, enhance T cell activation and TNF-α production, improve anti-tumor immunity, reduce tumor metastasis, and compare with other targets The drug has less toxicity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118922444A_ABST
    Figure CN118922444A_ABST
Patent Text Reader

Abstract

Described herein are anti-CCR8 antibodies, polynucleotides encoding the anti-CCR8 antibodies, host cells containing such polynucleotides, methods of making and using such anti-CCR8 antibodies or polynucleotides, pharmaceutical compositions containing such anti-CCR8 antibodies or polynucleotides, and methods of making and using such anti-CCR8 antibodies or polynucleotides. And mixtures or bispecific antibodies comprising such anti-CCR8 antibodies or polynucleotides encoding such mixtures or bispecific antibodies.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention is in the field of antibodies and their use in treating various human diseases.

[0002] This application contains a sequence listing (.xml) submitted electronically at the same time, named 126861-0006WO01_Sequence Listing, dated January 13, 2023, and with a file size of 82.1KB. Background Art

[0003] Regulatory T cells (defined as CD4+CD25+FoxP3+) are involved in preventing autoimmune reactions and limiting the extent and duration of immune responses to various inflammatory events (Tanaka, A. and Sakaguchi, S., Eur J Immunol. 2019Aug; 49(8): 1140-1146.doi: 10.1002 / eji.201847659). Although regulatory T cells (Treg or T reg) are relatively rare in peripheral circulation, they can account for up to 50% of CD4+T cells in tumors (Togashi et al., Nat Rev Clin Oncol. 2019Jun; 16(6): 356-371.doi: 10.1038 / s41571-019-0175-7). Specifically, regulatory T cells prevent the immune system from long-term or excessive responses to mild inflammatory events, or responses to normal tissues. Whether in tumors or peripheral tissues, Tregs inhibit immune cell activation and limit the activity of CD8+ effector T cells. Treg-mediated immunosuppression in the periphery is beneficial because it prevents excessive or disproportionate immune responses to minor injuries such as dermatitis. However, immunosuppression in the tumor microenvironment allows tumor cells to escape immune surveillance, proliferate, and eventually metastasize.

[0004] Treg can mediate immunosuppression through multiple mechanisms (Li C. et al., Molecular cancer 2020; 19:116). 1. The secretion of inhibitory cytokines including IL-10, TGF-β, IL-35, etc. plays a role in suppressing immune function through IL-10 and other pathways. Treg can also inhibit CD8+T cells and DCs through membrane-bound TGF-β, thereby regulating the body's anti-tumor immune function. 2. Granzymes and perforins kill effector cells. Granzymes and perforins are the main molecules that mediate the cytotoxicity of CTL, NK and other cells. 3. Treg affects effector cell function by interfering with cell metabolism mainly in the following three ways: (1) Deprivation of interleukin-2 (IL-2) in the TME. The growth of Treg and effector T cells requires the maintenance of IL-2. (2) CD39 and CD73 are nucleases constitutively expressed in human and mouse Treg. They can hydrolyze extracellular ATP or ADP into AMP and produce adenosine. Treg promotes adenosine production in the TME by producing extracellular enzymes CD39 and CD73, and produces inhibitory and antiproliferative effects by binding to adenosine receptor A2A on the surface of effector cells. (3) Treg transfers increased amounts of cAMP to effector T cells through gap junctions to interfere with their metabolism. 4. Affects the differentiation and proliferation of Treg by regulating DC. CTLA-4 expressed by Treg combines with CD80 and CD86 on the surface of DC to downregulate costimulatory signals. Lymphocyte activation gene 3 (LAG3) molecules expressed by Treg can inhibit the expression of MHC II molecules in DC. DC tolerance can be induced by the above two methods, and the latter can further induce T cell anergy through IDOc. 5. Changes in the functional crosstalk between Treg and MDSC. Factors produced by both MDSC and Treg form a positive feedback loop to promote the expansion of each population and strengthen the inhibitory environment. On the one hand, MDSC promotes the induction of Treg by producing molecules including TGF-β, IL10, CD73 and IDO. On the other hand, Tregs can also regulate the expansion and function of MDSCs by secreting IL-35 and TGF-β. In addition, cell surface molecular interactions including CD40 / CD40L, PD-1 / PD-L1, and CD80 / CTLA-4 can promote the functions of both MDSCs and Tregs.

[0005] To evade the host immune system, cancers of various etiologies increase the number of regulatory T cells within tumors. The disproportionate increase in regulatory T cells within patient tumors suppresses their natural anti-tumor responses and weakens the anti-tumor response induced by immunotherapy. Current approaches aimed at eliminating regulatory T cells within tumors also kill activated T cells or regulatory T lymphocytes outside the tumor. Therefore, they are either counterproductive or too toxic.

[0006] There is an unmet need for therapeutic approaches that can selectively inhibit or kill Tregs within tumors to provide, restore or enhance anti-tumor immunity. The present invention is dedicated to meeting this need by targeting CC motif chemokine receptor 8 (CCR8) with a specific antibody drug. Summary of the invention

[0007] Described herein are anti-CC motif chemokine receptor 8 (anti-CCR8) antibodies and mixtures containing anti-CCR8 antibodies, nucleic acids encoding these antibodies and mixtures, host cells containing these nucleic acids, pharmaceutical compositions comprising these antibodies, mixtures and nucleic acids, and methods of treatment comprising administering these antibodies, mixtures, nucleic acids or pharmaceutical compositions to a patient. The following numbered items describe these compositions and methods.

[0008] 1. An anti-CC motif chemokine receptor 8 (anti-CCR8) antibody comprising a heavy chain variable domain (V H ) V of complementarity determining region 1 (CDR1), CDR2 and CDR3 H and light chain variable domain (V L )V of CDR1, CDR2 and CDR3 L ,

[0009] Among them, anti-CCR8Mab 953 antibody V H CDR1, CDR2 and CDR3 have the amino acid sequences of SEQ ID NOs: 5, 6 and 7, respectively, and Mab 953 antibody V L CDR1, CDR2, and CDR3 have the amino acid sequences of SEQ ID NOs: 8, 9, and 10, respectively;

[0010] Among them, anti-CCR8Mab 1047 antibody V H CDR1, CDR2 and CDR3 have the amino acid sequences of SEQ ID NOs: 15, 16 and 17, respectively, and the Mab 1047 antibody V L CDR1, CDR2, and CDR3 have the amino acid sequences of SEQ ID NOs: 18, 19, and 20, respectively;

[0011] Among them, anti-CCR8Mab 1187 antibody V H CDR1, CDR2 and CDR3 have the amino acid sequences of SEQ ID NOs: 25, 26 and 27, respectively, and the Mab 1187 antibody V L CDR1, CDR2, and CDR3 have the amino acid sequences of SEQ ID NOs: 28, 29, and 30, respectively;

[0012] Among them, anti-CCR8Mab 1434 antibody V H CDR1, CDR2 and CDR3 have the amino acid sequences of SEQ ID NOs: 35, 36 and 37, respectively, and the Mab 1434 antibody V L CDR1, CDR2, and CDR3 have the amino acid sequences of SEQ ID NOs: 38, 39, and 40, respectively; and

[0013] in:

[0014] (a) The equilibrium dissociation constant (K) of the anti-CCR8 antibody binding to the amino-terminal extracellular domain of CCR8 D ) does not exceed 1 nM;

[0015] (b) K binding to the amino-terminal extracellular domain of CCR8 A At least 1×10 -6 , and / or

[0016] (c) ICs that block CCL1-mediated chemotaxis in P815 cells stably transfected with full-length human CCR8 protein 50 Less than 100ng / ml.

[0017] 2. The anti-CCR8 antibody according to item 1, wherein the anti-CCR8 antibody blocks the IC of CCL1-mediated chemotaxis in P815 cells stably transfected with human full-length CCR8 protein 50 Less than 50ng / ml.

[0018] 3. The anti-CCR8 antibody according to item 1, wherein the anti-CCR8 antibody binds to the amino-terminal extracellular domain of CCR8. D Not more than 0.8nM.

[0019] 4. The anti-CCR8 antibody according to item 1, wherein the anti-CCR8 antibody binds to the amino-terminal extracellular domain of CCR8. A At least 1.8×10 -6 .

[0020] 5. The anti-CCR8 antibody according to item 1, wherein the anti-CCR8 antibody binds to the amino-terminal extracellular domain of CCR8. D Not more than 0.7nM.

[0021] 6. The anti-CCR8 antibody according to item 1, wherein:

[0022] (1) V of the anti-CCR8Mab 953 antibody Hcomprising an amino acid sequence encoded by a polynucleotide encoding SEQ ID NO: 11, and the V L comprising an amino acid sequence encoded by a polynucleotide encoding SEQ ID NO: 12;

[0023] (2) V of the anti-CCR8Mab 1047 antibody H comprising an amino acid sequence encoded by a polynucleotide encoding SEQ ID NO: 21, and the V L comprising an amino acid sequence encoded by a polynucleotide encoding SEQ ID NO: 22;

[0024] (3) V of the anti-CCR8Mab 1187 antibody H comprising an amino acid sequence encoded by a polynucleotide encoding SEQ ID NO: 31, and the V L comprising an amino acid sequence encoded by a polynucleotide encoding SEQ ID NO: 32; and

[0025] (4) V of the anti-CCR8Mab 1434 antibody H comprising an amino acid sequence encoded by a polynucleotide encoding SEQ ID NO: 41, and the V L Comprising an amino acid sequence encoded by a polynucleotide encoding SEQ ID NO:42.

[0026] 7. The anti-CCR8 antibody according to item 6, wherein:

[0027] (1) V of the anti-CCR8Mab 953 antibody H comprising the amino acid sequence of SEQ ID NO: 3, and the V L An amino acid sequence comprising SEQ ID NO: 4;

[0028] (2) V of the anti-CCR8Mab 1047 antibody H comprising the amino acid sequence of SEQ ID NO: 13, and the V L An amino acid sequence comprising SEQ ID NO: 14;

[0029] (3) V of the anti-CCR8Mab 1187 antibody H comprising the amino acid sequence of SEQ ID NO: 23, and the V Lcomprising the amino acid sequence of SEQ ID NO: 24; and

[0030] (4) V of the anti-CCR8Mab 1434 antibody H comprising the amino acid sequence of SEQ ID NO: 33, and the V L Comprising the amino acid sequence of SEQ ID NO:34.

[0031] 8. The anti-CCR8 antibody according to item 1, wherein the anti-CCR8 antibody is a human or humanized IgG antibody.

[0032] 9. The anti-CCR8 antibody according to item 8, wherein the anti-CCR8 antibody is an IgG1 or IgG3 antibody.

[0033] 10. The anti-CCR8 antibody according to item 8, wherein the anti-CCR8 antibody is an IgG2 or IgG4 antibody.

[0034] 11. The anti-CCR8 antibody according to item 9, wherein the anti-CCR8 antibody is an IgG1 antibody or an afucosylated IgG1 antibody.

[0035] 12. The anti-CCR8 antibody according to item 1, wherein the anti-CCR8 antibody does not comprise a hinge region, a second heavy chain constant domain (C H 2) and the third heavy chain constant domain (C H 3).

[0036] 13. A mixture or bispecific antibody,

[0037] (a) wherein the mixture or bispecific antibody is a mixture, and the mixture comprises the anti-CCR8 antibody according to item 1 and a second antibody or a targeted inhibitor, wherein:

[0038] (1) (i) the second antibody is PSB205 Mab Pair, or binds to an antigen selected from the group consisting of programmed cell death protein 1 ligand 1 (PDL1), programmed cell death protein 1 ligand 2 (PDL2), programmed cell death protein 1 (PD1), cytotoxic T lymphocyte-associated protein 4 (CTLA4), CD20, cancer antigens, colony stimulating factor 1 receptor (CSF-1R) and viral antigens, or (ii) the second antibody is an agonist antibody that binds to CD27, CD40, tumor necrosis factor receptor superfamily member 4 (OX40), glucocorticoid-induced TNFR-related gene (GITR) or tumor necrosis factor receptor superfamily member 9 (4-1BB); or

[0039] (2) the targeted inhibitor targets an interaction involving a protein, wherein the protein is selected from the group consisting of PDL1, PDL2, PD1, CTLA4, LILRB1, LILRB2, MIC-A and MIC-B, cancer antigens, CSF-1R and viral antigens; or

[0040] (b) wherein the mixture or bispecific antibody is a bispecific antibody, and the bispecific antibody comprises the anti-CCR8 antibody according to item 1 and another antibody, wherein:

[0041] (1) the other antibody binds to an antigen selected from the group consisting of PDL1, PDL2, PD1, CTLA4, CD20, LILRB1, LILRB2, MIC-A and MIC-B, cancer antigens, CSF-1R and viral antigens, or

[0042] (2) The other antibody is an agonistic antibody that binds to CD27, CD40, OX40, GITR or 4-1BB.

[0043] 14. The mixture or bispecific antibody according to item 13, wherein the cancer antigen is selected from the group consisting of HER2, EGFR, SLAMF-7, Claudin 18.2, CD20, CD33, CD38, CD123 and B7H4.

[0044] 15. The mixture or bispecific antibody according to item 13,

[0045] The mixture is an antibody mixture comprising the anti-CCR8 antibody according to item 1, and the second antibody of the mixture or the other antibody of the bispecific antibody is an anti-cancer antigen antibody.

[0046] 16. The mixture or bispecific antibody according to item 15, wherein:

[0047] (a) the mixture or bispecific antibody is a mixture, and the second antibody of the mixture is an anti-PD1 antibody, wherein the second antibody inhibits the interaction between human PD1 (hPD1) and human PDL1 (hPDL1); or

[0048] (b) wherein the mixture or bispecific antibody is a bispecific antibody, and the other antibody of the bispecific antibody is an anti-PD1 antibody, wherein the other antibody inhibits the interaction of hPD1 and hPDL1.

[0049] 17. The mixture or bispecific antibody according to item 16,

[0050] wherein the second antibody binds to an antigen selected from the group consisting of programmed cell death protein 1 ligand 1 (PDL1), programmed cell death protein 1 ligand 2 (PDL2), programmed cell death protein 1 (PD1), cytotoxic T lymphocyte-associated protein 4 (CTLA4), CD20, cancer antigens, colony stimulating factor 1 receptor (CSF-1R) and viral antigens, or (ii) the second antibody is an agonist antibody that binds to CD27, CD40, tumor necrosis factor receptor superfamily member 4 (OX40), glucocorticoid-induced TNFR-related gene (GITR) or tumor necrosis factor receptor superfamily member 9 (4-1BB).

[0051] 18. The mixture or bispecific antibody according to item 15,

[0052] (a) wherein the mixture or bispecific antibody is a mixture, and the second antibody of the mixture is an anti-CTLA4 antibody, wherein the second antibody inhibits the interaction of human CTLA4 (hCTLA4) with human B lymphocyte activation antigen B7-1 (hB7-1) and / or human B lymphocyte activation antigen B7-2 (hB7-2); or

[0053] (b) wherein the mixture or bispecific antibody is a bispecific antibody and the other antibody of the bispecific antibody is an anti-CTLA4 antibody, wherein the other antibody inhibits the interaction of hCTLA4 with hB7-1 and / or hB7-2.

[0054] 20. The mixture or bispecific antibody according to item 15, wherein the second antibody of the mixture or the other antibody of the bispecific antibody is an anti-cancer antigen antibody.

[0055] 21. A mixture or bispecific antibody according to item 20, wherein the cancer antigen is selected from the group consisting of epidermal growth factor receptor (EGFR), V-ERB-B2 avian erythroblastic leukemia viral oncogene homolog 2 (HER2), epithelial cell adhesion molecule (EpCAM), phosphatidylinositol proteoglycan 3 (GPC3), tumor necrosis factor receptor superfamily member 17 (TMFRSF17, referred to herein as BCMA), CD20, tight junction protein-18.2 and prostate specific antigen (PSA).

[0056] 22. The mixture or bispecific antibody according to item 21, wherein the second antibody of the mixture or the other antibody of the bispecific antibody is an anti-claudin-18.2 antibody, an anti-CD20 antibody, an anti-HER2 antibody or a PSB205 MabPair.

[0057] 23. The mixture or bispecific antibody according to item 13, which is a bispecific antibody, wherein the bispecific antibody is an IgG antibody.

[0058] 24. One or more polynucleotides encoding the anti-CCR8 antibody according to item 1.

[0059] 25. One or more vectors comprising one or more polynucleotides according to item 24.

[0060] 26. One or more vectors according to item 25, which are viral vectors.

[0061] 27. One or more polynucleotides encoding the mixture or bispecific antibody according to item 13.

[0062] 28. One or more vectors comprising one or more polynucleotides according to item 27.

[0063] 29. One or more vectors according to item 28, which are viral vectors.

[0064] 30. A host cell comprising one or more polynucleotides according to item 27 or one or more vectors according to item 28.

[0065] 31. The host cell according to item 30, which is a mammalian cell.

[0066] 32. The host cell according to item 31, which is a CHO cell or a mouse myeloma cell.

[0067] 33. A method for preparing an anti-CCR8 antibody, comprising the following steps:

[0068] (a) introducing one or more polynucleotides according to item 24 into a host cell;

[0069] (b) culturing the host cell in a culture medium; and

[0070] (c) recovering the anti-CCR8 antibody from the culture medium or the host cell pellet.

[0071] 34. The method according to item 33, wherein

[0072] The anti-CCR8 antibody is a human, humanized or chimeric IgG antibody.

[0073] 35. A method for treating a cancer patient, comprising administering the anti-CCR8 antibody according to item 1 to the patient.

[0074] 36. A method for treating a cancer patient, comprising administering to said patient the mixture or bispecific antibody according to item 13.

[0075] 37. The method according to item 35, wherein the antibody is administered by injection into a tumor.

[0076] 38. The method according to item 36, wherein the mixture or bispecific antibody is administered by injection into a tumor.

[0077] 39. The method according to item 35, wherein the anti-CCR8 antibody is administered parenterally.

[0078] 40. The method according to item 36, wherein the mixture or bispecific antibody is administered by injection into a tumor.

[0079] 41. A method of treating a cancer patient, comprising:

[0080] (a) administering to the patient a bispecific antibody comprising (1) the anti-CCR8 antibody according to item 1, and (2) an antibody that binds to claudin 18.2, CD20, PDL1, PDL2, PD1, HER2, EGFR, CTLA4, GITR, leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1), LILRB2, LILRB3, LILRB4, LILRB5, CD24, MICA or MICB, or an agonistic antibody that binds to CD27, CD40, OX40, GITR or 4-1BB;

[0081] (b) administering to the patient one or more polynucleotides or vectors encoding the bispecific antibody of (a);

[0082] (c) administering to the patient (1) the anti-CCR8 antibody according to item 1 and (2) one or more of the following additional antibodies: PSB205 Mab Pair, or antibodies that bind to tight junction protein 18.2, CD20, PDL1, PDL2, PD1, HER2, EGFR, CTLA4, GITR, leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1), LILRB2, LILRB3, LILRB4, LILRB5, CD24, MICA, MICB, or agonistic antibodies that bind to CD27, CD40, OX40, GITR or 4-1BB; or

[0083] (d) administering to the patient one or more polynucleotides or vectors encoding the antibody of (c);

[0084] Wherein (c) the anti-CCR8 antibody of (1) or one or more polynucleotides or vectors encoding the same is administered to the patient before, after or simultaneously with (c) the one or more additional antibodies of (2) or one or more polynucleotides or vectors encoding the one or more additional antibodies.

[0085] 42. The method according to item 35, wherein the patient is treated with a chemotherapeutic agent, radiation or a STING agonist before, after or simultaneously with the administration of the anti-CCR8 antibody.

[0086] 43. The method according to item 42, wherein the STING agonist is selected from ADU-S100, MK-1454, E7766, BMS-986301, IMSA101, SB 11285 and SNY1891.

[0087] 44. The method according to item 36, wherein the patient is treated with a chemotherapeutic agent, radiation or a STING agonist before, after or simultaneously with the administration of the mixture or bispecific antibody.

[0088] 45. The method according to item 44, wherein the STING agonist is selected from ADU-S100, MK-1454, E7766, BMS-986301, IMSA101, SB 11285 and SNY1891.

[0089] 46. ​​The method of claim 35, wherein the cancer is selected from the group consisting of Hodgkin's lymphoma, non-Hodgkin's lymphoma, Kaposi's sarcoma, T-cell leukemia and lymphoma, melanoma, breast cancer, renal cell carcinoma, head and neck cancer, anal cancer, laryngeal cancer, oral cancer, liver cancer, cervical cancer, stomach cancer, penis cancer, vaginal cancer, vulvar cancer, lung cancer, colon cancer, leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, lymphoma, esophageal cancer, hepatocellular carcinoma, pancreatic adenocarcinoma, pancreatic ductal adenocarcinoma, ovarian cancer, head and neck cancer, glioma, glioblastoma, squamous cell carcinoma, renal cell carcinoma, prostate cancer and bladder cancer.

[0090] 47. The method of claim 36, wherein the cancer is selected from the group consisting of Hodgkin's lymphoma, non-Hodgkin's lymphoma, Kaposi's sarcoma, T-cell leukemia and lymphoma, melanoma, breast cancer, renal cell carcinoma, head and neck cancer, anal cancer, laryngeal cancer, oral cancer, liver cancer, cervical cancer, stomach cancer, penis cancer, vaginal cancer, vulvar cancer, lung cancer, colon cancer, leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, lymphoma, esophageal cancer, hepatocellular carcinoma, pancreatic adenocarcinoma, pancreatic ductal adenocarcinoma, ovarian cancer, head and neck cancer, glioma, glioblastoma, squamous cell carcinoma, renal cell carcinoma, prostate cancer and bladder cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0091] Figures 1A-1D : Binding of anti-CCR8 Fab to recombinant huCCR8-N-terminal antigen (Seq No. 1). The binding affinity of anti-CCR8 Fab to huCCR8 N-terminal protein was determined by Biacore analysis. Digested anti-CCR8 Fab fragments were passed over the captured antigen. The binding affinity of (A) parent anti-CCR8 chimeric Fab455, (B) engineered anti-CCR8 Fab 953, (C) engineered anti-CCR8 Fab1047, (D) lead candidate Fab51 (1187) is shown.

[0092] Figures 2A-2D : Anti-CCR8 antibody 1187 binds to HEK293 cells or P815 cells transfected with full-length hCCR8. HEK293 cells (A) or P815 cells (B) transfected with hCCR8 (Seq No. 2) were stained with increasing concentrations of anti-CCR8 antibody. Binding of the antibody was detected by PE-conjugated goat anti-human Fc-specific secondary antibody and evaluated by flow cytometry. (C) Increasing concentrations of anti-CCR8 1187 and a benchmark anti-CCR8 antibody (Bayer antibody 23411) were incubated with P815 cells transfected with hCCR8. As in (A) and (B), binding of the antibody was detected using PE-conjugated anti-human IgG-Fc: Anti-CCR8 antibody 1187 showed higher binding affinity and intensity (MFI) than Bayer antibody 23411. (D) HEK293 cells transfected with an irrelevant GFP protein were incubated with 100 ug / ml of 1187 or Bayer antibody 23411. Antibody binding was detected using an APC-conjugated goat anti-human Fc specific secondary antibody. Unlike 1187, Bayer antibody 23411 showed non-specific binding to HEK293 cells.

[0093] Figures 3A-3H: Binding of CD4+T cells to anti-CCR8 antibodies. The binding of CD4+T cells from human PBMCs stimulated with anti-CD3 (10ug / ml OKT-3) to anti-CCR8 candidate antibodies (100μg / ml) was evaluated. MFI = mean fluorescence intensity. (A) The dot plot shows the gating strategy for activated CD4+Foxp3+ regulatory T cells, CD4+Foxp3-T cells, and CD4low monocytes. (B) Binding of anti-CCR8 antibodies to CD4+Foxp3+ regulatory T cells. Compared with anti-RSV and anti-DNP negative control IgG1 antibodies, anti-CCR8 lead candidate 1187 and backup candidates 953 and 1047 showed specific binding to 50-60% of CD4+Foxp3+T cells. (C) MFI of anti-CCR8 antibodies binding to CD4+Foxp3+ regulatory T cells. (D) MFI of anti-CCR8 antibody binding to CD4+Foxp3- regulatory T cells. Unlike 455 (parental chimeric antibody) and 10A11 (benchmark from Shionogi), anti-CCR8 1187 and alternate candidate 1047 showed no binding to CD4+Foxp3- T cells compared to anti-RSV (respiratory syncytial virus) and anti-DNP (dinitrophenyl antibody) negative control antibodies. Similarly, anti-CCR8 1187 and 1047 showed no binding to CD4low monocytes (E) and CD8+ T cells (F). (G) The binding of 1187 was also evaluated in resting and IL-2 stimulated PBMCs. In resting PBMCs, 1187 (20ug / ml) specifically binds to 15% of CD4+Foxp3+ T cells expressing higher levels of Foxp3. (H) Stimulation of PBMCs with IL-2 (200 U / ml) for 2 days did not change the pattern of 1187 binding.

[0094] Figure 4 : Polyreactive binding of anti-CCR8 antibodies to apoptotic cells. Jurkat T cells were treated with doxorubicin (17uM) overnight to induce apoptosis. Apoptotic cells were collected and incubated with various anti-CCR8 antibodies at a concentration of 100ug / ml. After washing three times with PBS, the binding of antibodies was detected with APC-coupled polyclonal goat anti-human Fc-specific antibodies. Lead candidate 1187 showed low polyreactive binding similar to B16 (Jounce Therapeutics), anti-RSV and anti-DNP control antibodies, while clone 953 and benchmarks 4A19 (Bristol Myers Squibb, BMS), K17 (Jounch Therapeutiics), Ab2-1 (Surface Oncology), 23411 (Bayer) and 10A11 (Shionogi) showed significantly higher binding.

[0095] Figure 5 : Cross-blocking to compare the binding epitopes of anti-CCR8 antibodies. Biotinylated 1187 was mixed with various unlabeled anti-CCR8 antibodies and negative control rituximab at a 1:1 molar ratio. The mixture was then added to hCCR8-transfected 293 cells and incubated for 30 minutes at room temperature. Binding of biotinylated 1187 was detected by APC-coupled streptavidin. Binding of biotinylated PSB114 was blocked by unlabeled 1187 and 4A19, indicating that the two antibodies have the same epitope. In contrast, antibodies 10A11, B16, K17, Ab2-1, 23411 and the negative control antibody rituximab did not compete for 1187 binding, indicating that they react with epitopes different from 1187.

[0096] Figures 6A-6E :Anti-CCR8 antibodies inhibit CCL1 signaling and CCL1-induced chemotaxis. (A) In the presence of 30nM CCL1, increasing concentrations of anti-CCR8 antibodies were added to CHO-CCR8β inhibitory protein reporter cells (Discover X). Both parent 455 and anti-CCR8 953 blocked CCL1-induced β inhibitory protein signaling. In addition, 953 alone without CCL1 did not induce any signaling, indicating that anti-CCR8 antibodies do not induce internalization of CCR8. (B) Inhibition of CCL1-mediated chemotaxis by anti-CCR8Fab in invasion assays (transwellassay). Fab fragments of anti-CCR8 antibodies were generated to eliminate avidity effects. In the presence of increasing concentrations of anti-CCR8Fab fragments (to inhibit CCL1 / CCR8 interactions and subsequent migration), chemotaxis of P815 cells expressing CCR8 was induced by 1nM huCCL1. (B) A representative experiment. (C) Fabs of 1187 and 1434 were compared to the whole IgG of the benchmark antibody (10A11) in the chemotaxis assay. Since the activity of the 10A11 Fab fragment was very low in preliminary experiments, 10A11 was used as whole IgG and started at a concentration of 10 μg / ml in this experiment, while 1187 and 1434 were used as Fab fragments and started at a concentration of 5 μg / ml. (D) IC values ​​of anti-CCR8 Fabs for inhibition of CCL1-mediated chemotaxis were measured. 50 Results are presented as IC of chemotaxis inhibition normalized to parental antibody 455. 50 The average IC of 455 50 The average IC of Fab fragments of 953, 1047, 1187 and 1434 for blocking CCL1-mediated chemotaxis is 14.17 + / - 2.5 ng / ml or 94 + / - 16 pM. 50150pM, 1088pM, 254pM and 414pM respectively. (E) Comparison of 1187 and benchmark products in inhibiting CCL1-induced chemotaxis. P815 cells transfected with hCCR8 were incubated with serial dilutions of 1187 or benchmark anti-CCR8 antibodies (all in complete IgG1 form). CCL1 (1nM) was used to induce invasion and migration as described above. Cells that migrated through the membrane were quantified using Cell Titer Glo (Promega). Lead candidate 1187 was more effective than 4A19 in inhibiting CCL1-induced chemotaxis, while benchmarks B16 and K17 showed only moderate to negligible inhibition.

[0097] Figures 7A-7C : Anti-CCR8 antibodies deplete Tregs in vitro. Human PBMCs were stimulated with OKT-3 in the presence of 10ug / ml anti-CCR8 antibodies. After five days in culture, cells were immunostained to identify CD4+Foxp3+T cells. (A) Representative dot plots for counting CD4+Foxp3+ regulatory T cells. (B) Antibodies 1187, 953, 1047 and benchmark 10A11 deplete approximately 50% of Tregs in PBMCs stimulated with various concentrations of OKT-3. (C) Human PBMCs were stimulated with 100ng / ml OKT-3 in the presence of increasing concentrations of anti-CCR8 antibodies. Antibodies 1187, 953 and 1047 were more potent at depleting CD4+Foxp3+Tregs than benchmark 10A11 from Shionogi Inc.

[0098] Figures 8A-8E:The reduction of fucose in 1187 increases the binding of Fcγ receptor III and the efficacy of Treg depletion. (A) Binding of 1187 and 1187+2FF (no fucosylation) to CHO cells transfected with human FcγR III. Bound antibodies were detected using flow cytometry with APC-labeled anti-human IgG secondary antibodies. (B) Anti-CCR8 antibodies were tested for Treg depletion in vitro using OKT-3 (100ng / ml) stimulated PBMCs. Compared with unmodified 1187 and 1047, no fucosylated anti-CCR81187 (1187+2FF) showed improved efficacy in in vitro Treg depletion. (C) Anti-CCR81187 and 1187+2FF (10ug / ml) were tested for Treg depletion using IL-2 stimulated PBMCs. Compared to unmodified 1187, afucosylated 1187 (1187+2FF) showed improved efficacy in in vitro depletion of CD4+Foxp3high cells. (D) Summary of the depletion effects of 1187 and 1187+2FF on different CD4 T cell populations in IL-2 stimulated PBMCs. (E) Anti-CCR8 1187 and 1187+2FF were tested for Treg depletion using fresh PBMCs. Compared to 1187, afucosylated 1187 (1187+2FF) showed improved efficacy in in vitro depletion of CD4+Foxp3high cells in fresh PBMCs.

[0099] Figures 9A-9G:PSB114 (1187+2FF) specifically depletes Foxp3high cells expressing GITR and ICOS with high potency. Freshly isolated PBMCs were incubated with serial dilutions of PSB114 for 4 to 5 days. The cells were then stained with Percp-Cy5.5-coupled anti-CD4 antibody, Alexa 488-coupled anti-GITR antibody, BV-421-coupled anti-ICOS antibody, and PE-coupled anti-Foxp3 antibody. The number of cells expressing Foxp3, Foxp3+GITR, and Foxp3+ICOS was counted using flow cytometry. In order to reduce the differences between samples, these cell numbers were normalized to the average number of CD4T cells recovered in different samples. (A) Flow cytometric analysis confirmed that PSB114 specifically reduced the number of Foxp3high GITR+ cells and Foxp3high ICOS high cells in CD4+Foxp3+T cells. (BF) Titration curves of PSB114 depletion of Foxp3+ cells, Foxp3+GITR+ cells, and Foxp3+ICOS+ cells in freshly isolated PBMCs. An irrelevant human IgG1 (10 ug / ml) was used as a negative control. (G) Summary of the EC50 of PSB114 potency. The mean EC50 of nine different donors was 23 ng / ml + / - 25.5 ng / ml (standard deviation).

[0100] Fig.10 : PSB 114-mediated depletion of Foxp3+ICOS+ cells is dependent on FCR IIIa. Treg depletion assays were established as shown in Figure 9. In the PSB114 group, anti-FCRIIIa antibodies (10ug / ml clone 3G8, Biolegend), anti-FCRIIa antibodies (10ug / ml clone AT10, Biorad) or anti-FCRIIIa+FcRIIa antibodies (10ug / ml each) were added to block the function of FCRIIIa or FCRIIa or both, respectively. Mouse IgG1 was added as an isotype control for anti-FCR IIIa or anti-FCRIIa antibodies. Samples containing hIgG1 (10ug / ml) or without any antibodies were used as controls for PSB114. PSB114 (10 ug / ml) depleted 90% of Foxp3+ICOS+ cells compared to hIgG1 or medium control, and this depletion was largely blocked by anti-FCRIIIa antibody, indicating that the depletion effect of PSB114 is mainly mediated through FCRIIIa.

[0101] Figures 11A-11B :PSB114(1187+2FF) mediates the expansion of monocytes. Fig.10The effect of PSB114 on monocytes was monitored during the Treg depletion assay described in . Monocytes in culture are distinguished from lymphocytes by their larger size. (A) PSB114 induces an increase in large monocytes over a concentration range of 1 ug / ml to 10 ug / ml. (B) Blocking FCRIIIa or FCRIIa alone resulted in a small reduction in monocyte expansion, and the combination of anti-FCRIIIa and anti-FCRIIa showed an additive effect.

[0102] Figures 12A-12F :Anti-CCR8 antibodies enhance T cell activation. PBMCs from 3-5 different donors were stimulated with OKT-3 at different concentrations for 5 days in the presence of anti-CCR8 antibodies (10 μg / ml). On the 4th day of stimulation, Edu (a thymidine analog) was added for incorporation into proliferating cells. On the 5th day, cells and supernatants were harvested. (A) The cells were stained with anti-CD4 and anti-CD8, fixed and permeabilized. The incorporation of Edu in proliferating cells was detected by Click-it reaction, and the number of proliferating cells was counted by flow cytometry. (B) Results from one donor are shown. (C) Summary of the results from PBMCs from three donors stimulated with 100 ng / ml OKT-3. The results were normalized to the hIgG1 control. Anti-CCR8 1187, 953 and 1047 are more effective than 455 (parent) in enhancing T cell proliferation. (D) TNF-α levels in the supernatant from (B) were determined by ELISA. (E) Summary of anti-CCR8 antibody induction of TNF-α production from PBMCs of five donors stimulated with 100 ng / ml OKT-3. The fold increase in TNF-α was normalized to the hIgG1 control. (F) PBMCs were stimulated with 100 ng / ml OKT-3 in the presence of increasing concentrations of anti-CCR8 antibodies. TNF-α levels in the supernatant were determined by ELISA. Antibodies 1187 and 953 were more effective than the benchmark 10A11 in promoting TNF-α production.

[0103] Figures 13A-13E: Anti-CCR8 antibody 1187 depletes Treg in vivo. MDA-MD232 tumors were implanted into NSG mice transplanted with CD34+ human stem cells and treated with carrier or 1187 or 1187+2FF. The percentage and absolute number of CD4+Foxp3+CD25+ regulatory T cells, CD56+NK cells and CD8T cells were counted by flow cytometry. In both spleen (A) and tumor (B), fucose-reduced antibody 1187 (1187+2FF) showed significantly stronger efficacy in Treg cell depletion compared to unmodified 1187. Tregs in tumors of mice treated with 1187+2FF were reduced by 20 times, while only a 2.8-fold reduction was observed in the spleen. 1187+2FF treatment increased the number of NK cells (C) and CD8T cells (D) in tumors. (E) The levels of various cytokines in serum samples collected from treated mice were assessed using the Legendplex bead array assay (Biolegend). As the anti-tumor immune response was enhanced, IP-10 levels were significantly higher in the serum of mice treated with fucose-reduced anti-CCR8 1187 (1187+2FF), while the levels of other cytokines remained unchanged.

[0104] Figures 14A-14D : Fucose-reduced anti-CCR8 antibody 1187 (1187+2FF) inhibits tumor growth in hCCR8 knock-in mice. MC38 tumor cells were implanted into hCCR8 knock-in mice (Biocytogen), and once the tumor size reached 100 mm 3 Treatment with vehicle or 1187+2FF (n=6 in each group). (A) Mean increase in tumor size in vehicle and 1187+2FF treated groups. *P<0.05, two-way ANOVA with repeated measures over time. (B) Tumor growth in individual mice treated with vehicle. (C) Tumor growth in individual mice treated with 1187+2FF. (D) Flow cytometric analysis of tumor infiltrating cells from vehicle and 1187+2FF treated groups.

[0105] Figures 15A-15F : The combination of PSB114 (1187+2FF) and anti-PD1 antibody showed synergistic effect in inhibiting MC38 tumor growth in hCCR8 knock-in mice. MC38 tumors were implanted into hCCR8 knock-in mice as described in Figure 14. Once the average tumor size reached 100 mm 3, mice were randomly divided into groups and treated with vehicle, PSB114, anti-mouse PD1 antibody (RMP 1-14, BioXcel), or PSB114 + anti-mouse PD1 antibody. (A) Mean increase in tumor size in groups treated with vehicle, PSB114, anti-mouse PD1 antibody, and PSB114 + anti-mouse PD1 antibody. *P<0.0001, two-way ANOVA with repeated measures over time. (BE) Tumor growth in individual mice treated as described in A. (F) Flow cytometric analysis of tumor-infiltrating CD45+ cells in treatment groups. Groups treated with vehicle and PSB114 were analyzed on day 29. Groups treated with anti-mouse PD1 antibody and anti-mouse PD1 antibody + PSB114 were analyzed on day 42. PSB114 reduced the percentage of CD4+Foxp3+Tregs and increased the CD8 T cell / Treg ratio at day 29 when used as a single agent or in combination with anti-mouse PD-1 antibody at day 42.

[0106] Figures 16A-16D :PSB114 (1187+2FF) inhibits the growth of anti-PD1 antibody-tolerant B16F10 tumors in hCCR8 knock-in mice. Anti-PD1 antibody-tolerant B16F10 tumor cells were transplanted into hCCR8 knock-in mice. When the average tumor size reached 50 mm 3 Mice were treated with vehicle or anti-mouse PD1 antibody (10 mg / kg) or PSB114 (1187+2FF 10 mg / kg) at 4 pm. (A) Average tumor size growth in vehicle, anti-mouse PD1 antibody, and PSB114 treatment groups. (BD) Tumor growth of individual mice treated as described in (A). One-way ANOVA test was used to calculate the statistical significance between tumor sizes at day 15 (*p<0.01).

[0107] Figures 17A-17C : In vivo half-life of 1187+2FF. Human FcRn transgenic mice Tg32 (Jacksonlaboratory) were injected with a single 5 mg / kg dose of 1187+2FF, 1047, 953 or control antibody (rituximab). The level of circulating antibodies from plasma samples was measured by anti-human IgG ELISA. (A) The percentage of remaining anti-CCR8 antibodies at different time points after day 1. (B) Half-life of anti-CCR8 antibodies. (C) Clearance rate of anti-CCR8 antibodies. Fucose-reduced anti-CCR8 1187 (1187+2FF) showed a half-life and clearance rate similar to that of the control antibody rituximab.

[0108] Brief description of sequence listing

[0109]

[0110] DETAILED DESCRIPTION

[0111] Described herein are antibodies that bind to CCR8, such as human and / or cynomolgus monkey CCR8, and antibody mixtures comprising an anti-CCR8 antibody and a second antibody that binds to a second antigen, the second antigen being, for example, (1) a cancer antigen, such as HER2, EGFR, CEA, CD123, B7H4, B7H3, CD19, CD20, CD37, CD38, Claudin 18.2, GPC3, or BCMA, etc., (2) a checkpoint molecule, such as PD1, PDL1, CTLA4, or GITR, etc., or (3) a protein expressed on cells that suppress immune responses, such as myeloid-derived suppressor cells (MDSC) or regulatory T cells (Treg), including, for example, CSF-1R. In addition, the second antibody in the mixture of the anti-CCR8 antibody and the second antibody can be an agonist antibody that binds to, for example, CD27, CD40, OX40, GITR, or 4-1BB. In addition, the second antibody in the mixture of the anti-CCR8 antibody and the second antibody can be the checkpoint inhibitor PSB205MabPair described in US11,124,570, all the contents of which are incorporated by reference as a whole for all purposes. Also described are bispecific antibodies, which include one or more variable domains from each of the two antibodies, the antibodies may be anti-CCR8 antibodies and antibodies that bind to the second antigen associated with the antibody mixture described in the context. A mixture comprising an anti-CCR8 antibody and a targeted inhibitor is further described herein. A method for preparing an antibody or antibody mixture described herein using a single host cell line is also described herein. Polynucleotides encoding these antibodies and mixtures, host cells containing such polynucleotides, and methods of treating using these antibodies, mixtures (including antibody mixtures) and polynucleotides are further described herein.

[0112] CCR8 is a seven-transmembrane G protein-coupled protein that is highly expressed in regulatory T cells within tumors rather than outside tumors. It is also not present on activated T cells. It is reported that CCL1, CCL4, CCL16, CCL17, CCL18 and mouse CCL8 can bind to CCR8. However, CCR8 is the only receptor for chemokine CCL1 (Korbecki et al., Int. J. Mol. Sci. 2020, 21, 7619; doi: 10.3390 / ijms21207619). These chemokine ligands act as induction signals. Therefore, Treg expressing CCR8 undergoes chemotaxis and migrates to ligands such as CCL1 produced by tumor-associated macrophages and cancer-associated fibroblasts. In addition, the expression of CCL1 in lymph nodes promotes the migration and metastasis of cancer cells expressing CCR8 (Das et al., J Exp Med. 2013 Jul 29; 210 (8): 1509-28. doi: 10.1084 / jem.20111627). By overexpressing CCL1, the tumor microenvironment attracts regulatory T cells expressing CCR8. The chemokine CCL1 interacts with CCR8 through its N-terminus and the second extracellular domain. The CCL1-CCR8 interaction can induce regulatory T cells to migrate to the tumor, thereby inhibiting anti-tumor immunity.

[0113] In breast cancer patients, CCR8 expression is highly enriched on tumor-associated Tregs compared to circulating peripheral Tregs (Plitas et al., Immunity. 2016 Nov 15; 45(5): 1122-1134. doi: 10.1016 / j.immuni.2016.10.032). In addition, increased expression of CCR8 has been observed in several types of cancers, including breast cancer, colorectal cancer, and melanoma, and is associated with poor clinical prognosis (Magnuson et al., Proc Natl Acad Sci U S A. 2018 Nov 6; 115(45): E10672-E10681. doi: 10.1073 / pnas.1810580115). CCR8 ligands CCL1 and CCL18 are also expressed more in several types of cancer. Clinical and in vitro data indicate that the chemokine CCL1 is involved in the recruitment and activation of Tregs. Treg-mediated suppression of T cell antitumor activity is a problem in many types of cancer, limiting the effectiveness of T cell-directed immunotherapy. Anti-CCR8 antibody therapy could reduce the Treg-mediated antitumor immunosuppression that accompanies many current checkpoint inhibitor-directed therapies, thereby improving their effectiveness. Anti-CCR8 antibodies that primarily deplete intratumoral Tregs may have less toxicity than other antibodies that target peripheral Tregs. Blockade of CCR8 could further reduce tumor cell metastasis.

[0114] A novel high-affinity anti-CCR8 antibody is described herein, which blocks the chemotactic response to CCL1 and specifically eliminates regulatory T cells expressing CCR8. It is envisioned herein that the antibody is more effective and safer than current regulatory T cell targeted drugs. In one embodiment, the anti-CCR8 antibody provided herein targets the N-terminus of CCR8 to increase antibody affinity and enhance the blocking of CCL1-CCR8 interaction. In addition, in other embodiments, the targeted amino acid residues in both the CDR and the framework region are iteratively replaced to increase binding affinity and specificity. The resulting antibody has a high affinity for CCR8 and a high specificity for activated regulatory T cells. It blocks the chemotactic response to CCL1 and depletes activated regulatory T cells expressing CCR8 with low nanomolar efficiency. It enhances TNFα production in T cell activation and activated PBMCs. In other embodiments, the anti-CCR8 antibody of the present invention preferentially depletes tumor-infiltrating regulatory T cells and increases the infiltration of anti-tumor NK and CD8T cells in tumors. In other embodiments, the ADCC activity of the anti-CCR8 antibodies of the invention is further enhanced by production in a culture containing the fucose analog 2-fluoro-fucose (2FF) to produce fucose-reduced (afucosylated) antibodies.

[0115] As used herein, the term "afucosylated" or grammatical variants thereof refers to an antibody of the invention having a reduced amount of fucosylation of N-linked carbohydrate structures in the Fc region compared to the same antibody produced in normal CHO cells. In a specific embodiment, the afucosylated antibody has a trimannosyl core structure of complex N-glycans, and the Fc has no fucosyl residues. Due to the enhanced binding capacity of FcγRIIIa, these glycoengineered antibodies lacking core fucosyl residues of Fc N-glycans can exhibit stronger ADCC than fucosylated equivalents.

[0116] Unlike existing therapeutic agents such as anti-CTLA-4 antibodies, anti-CD25 antibodies, and anti-CCR4 antibodies that are intended to eliminate regulatory T cells, in certain embodiments, the anti-CCR8 antibodies of the present invention have been found to be more specific for tumor-infiltrating regulatory T cells. This specificity contemplated herein can prevent the toxicity observed in existing treatments. Unlike the anti-CCR8 antibodies of the prior art, the anti-CCR8 antibodies of the present invention provided herein have been found to have an advantage in that there is little or no off-target binding and are therefore believed to provide a longer therapeutic effect. In other embodiments, the anti-CCR8 antibodies of the present invention provided herein also have excellent efficacy in blocking CCL1 responses, which is a mechanism for preventing regulatory T cell immunosuppression.

[0117] In a specific embodiment, the anti-CCR8 antibodies of the present invention provided herein can be combined with proteins encoded by various human and cynomolgus monkey alleles of CCR8 at the N-terminal extracellular domain of the protein. In other embodiments, the anti-CCR8 antibodies provided herein can inhibit the growth of cancer cells and / or tumors and / or kill them by selectively inhibiting, suppressing and / or killing Tregs, thereby promoting, inducing, restoring and / or enhancing immunity against such cancer cells and tumors. In addition, a mixture comprising an anti-CCR8 antibody as described herein and a second antibody bound to another protein as described in the context can inhibit the growth of cancer cells and / or tumors and / or kill them. Finally, a bispecific antibody comprising one or more variable domains from an anti-CCR8 antibody and an antibody bound to another protein (e.g., a cancer antigen) as described in the context can inhibit the growth of cancer cells and / or tumors and / or kill them.

[0118] definition

[0119] As used herein, an "agonist" is a molecule that mimics or enhances a specific biologically active molecule or pathway. For example, a protein expressed on the surface of a cell may mediate the downstream effects of a molecule or pathway when a cytokine binds to the protein. An agonist of the protein may elicit a similar, greater, or lesser effect (compared to the effect elicited by the cytokine) when interacting with the protein, although the agonist may or may not compete with the cytokine for binding to the protein.

[0120] As used herein, an "antagonist" is an agent that blocks or inhibits the activity of a specific biologically active molecule. For example, a specific protein, when interacting with its binding partner, may activate a biological pathway with known downstream effects. An antagonist or inhibitor of the protein and / or its binding partner may optionally mitigate or eliminate these downstream effects by blocking or inhibiting the interaction of the protein with its binding partner.

[0121] An "antibody" as referred to herein is an antibody comprising at least one V H or V L Antibodies usually contain both V H and V L Both. H and V LThe invention is described in detail in, for example, Kabat et al., SEQUENCES OF PROTEINS OF IMMUNOLOGICAL INTEREST, Fifth Edition, US Department of Health and Human Services, Public Health Service, National Institutes of Health, NIH Publication No. 91-3242, 1991, pages xvi-xix and 103-533, which is incorporated herein by reference. "Antibodies" include molecules in different forms, such as single-chain Fv antibodies, scFv antibodies (which comprise V and V linked by a linker), H and V L ), Fab, F(ab')2, Fab' and scFv: Fc antibodies (as described in Carayannopoulos and Capra, FUNDAMENTAL IMMUNOLOGY, 3rd edition, Chapter 9, Paul ed., Raven Press, New York, 1993, pp. 284-286, which is incorporated herein by reference), Antibodies, single domain antibodies, bispecific antibodies, Fab-scFv, DVD-IgG, IgG(H)-scFv, nanobodies, nanobodies-HSA, diabodies, DARTs, TandAbs, scDiabodies, miniantibodies, minibodies, etc. (see, e.g., Spiess et al., (2015), Alternative molecular formats and therapeutic applications for bispecific antibodies, Molecular Immunology 67:95-106), as well as IgG antibodies defined below and many other possible formats.

[0122] "Bispecific antibody" as referred to herein is an antibody comprising at least one variable domain from a first antibody that binds to a first epitope or antigen and at least one variable domain from a second antibody that binds to a second epitope or antigen. In some cases, the first and second epitopes will be located on different molecules, optionally on different proteins. Therefore, in some cases, the first and second antibodies will bind to different antigens. Bispecific antibodies can have various forms. For example, bispecific antibodies can be bispecific T cell engagers (BiTEs), dual affinity retargeting proteins (DARTs), double antibodies, tandem double antibodies (TandAbs) or IgG antibodies, as well as many possible forms. See, for example, Wang et al., (2019), Design and Production of Bispecific Antibodies, Antibodies 8, 43 (30 pages), which is incorporated herein by reference in its entirety, and Spiess et al., (2015), Alternative molecular formats and therapeutic applications for bispecific antibodies, Molec. Immunol. 67: 95-106, which is incorporated herein by reference in its entirety. Each of these exemplary formats comprises V from two different antibodies that bind to different epitopes. H and V L Both. A bispecific antibody may comprise a promoter V H and V L The invention also provides a method for modifying the homologous pairing of the bispecific antibody, which is referred to herein as a partner-directed change and is discussed in the context. If the bispecific antibody is an IgG antibody consisting of two heavy chains (each heavy chain is from two different antibodies) and two light chains (each light chain is from one of the two different antibodies), it can also include changes that can promote the formation of heterodimeric HC / HC pairing. Many such changes are known in the art.

[0123] "Cancer antigens" as referred to herein are molecules that are abundantly expressed on the surface of cancer cells, optionally proteins. The expression of cancer antigens is high enough so that it can be detected by typical immunohistochemistry (IHC). See, for example, Parra et al., (2018), Appl.Immunohistochem.Mol.Morphol.26(2):83-93. Cancer antigens are expressed at variable levels in different cancer cells, and are also expressed at least to a certain extent on normal cells. In some cases, cancer antigens are expressed only on cancer cells. For example, a rearranged form of the epidermal growth factor receptor (EGFR), referred to as EGFRvIII, is expressed on glioblastoma cells, but not on normal cells. In another example, carcinoembryonic antigen (CEA) is expressed in normal tissues during fetal development, but not after birth. CEA is expressed in certain cancer cells. Therefore, both EGFRvIII and CEA are cancer antigens as referred to herein. Other examples of cancer antigens include proteins encoded by genes including EGFR, V-ERB-B2 avian erythroblastic leukemia viral oncogene homolog 2 (HER2), epithelial cell adhesion molecule (EpCAM), glypican 3 (GPC3), tumor necrosis factor receptor superfamily member 17 (TMFRSF17, referred to herein as BCMA), claudin-18.2, CD20, and prostate-specific antigen (PSA), among others.

[0124] "Charged" amino acids as referred to herein are acidic or basic amino acids that can have a charge at near physiological pH. These amino acids include the acidic amino acids glutamic acid (E) and aspartic acid (D) that are negatively charged at physiological pH, and the basic amino acids arginine (R) and lysine (K) that are positively charged at physiological pH. The weakly basic amino acid histidine that can be partially charged at near physiological pH is not within the definition of "charged" amino acids herein. To avoid confusion, the positive charge referred to herein is considered to be "opposite" to the negative charge. Thus, for example, the charges of the amino acids glutamic acid (E) and arginine (R) are opposite.

[0125] "Clearance" of an antibody in vivo refers to the elimination of the antibody, which can be detected as the elimination or reduction of the amount of the antibody in the bloodstream or other tissues of a mammal. Typically, to determine the clearance rate, the antibody is administered to the mammal, and the blood or tissues of the mammal are then sampled and quantitatively tested for the presence of the antibody at regular intervals. From these tests, the in vivo half-life (T 1 / 2 ) and / or area under the curve (AUC) value. 1 / 2Or the reduction of AUC indicates the increase of clearance referred to herein. An exemplary method for determining whether the clearance of the human IgG antibody changed in mice is increased or decreased relative to the unaltered antibody comprises the following steps. The unaltered and changed antibodies can be injected subcutaneously (e.g., under the skin on the shoulder) into a separate mouse. A whole blood sample of about 0.1 mL can be collected by retroorbital sinus puncture at each time point. The blood can be coagulated and processed to obtain serum. The presence of human antibodies in serum samples can be determined using antibodies specific for human Fc, such as commercially available immunoassay systems (e.g., one of the immunoassay systems available from Gyros US, Inc., Warren, NJ, USA). For example, blood samples can be collected at 0, 0.5, 2, 8, 24, 72, 120, 168, 240, 312, 384 and 480 hours after injection. Pharmacokinetic parameters can be estimated from serum concentrations using, for example, Phoenix.RTM.6.3 software (Pharsight, Sunnyvale, CA, USA).

[0126] "Chemotherapeutic agents" target dividing cells, interfering with processes associated with cell division, such as DNA replication, RNA synthesis, protein synthesis, assembly, disassembly or function of the mitotic spindle, and / or the synthesis or stability of molecules such as nucleotides or amino acids that play a role in these processes. Thus, chemotherapeutic agents can kill cancer cells and other dividing cells. Chemotherapeutic agents are well known in the art. They include, for example, the following agents: alkylating agents (e.g., busulfan, temozolomide, cyclophosphamide, lomustine (CCNU), streptozotocin, methyllomustine, cis-diamine dichloroplatinum, thiotepa, and aziridinylbenzoquinone); inorganic ions (e.g., cisplatin and carboplatin); nitrogen mustards (e.g., melphalan hydrochloride, chlorambucil, ifosfamide, and nitrogen mustard hydrochloride); nitrosoureas (e.g., carmustine (BCNU)); antitumor antibiotics (e.g., doxorubicin, daunorubicin, mithramycin, daunomycin, idarubicin, mitomycin C, and bleomycin); plant derivatives (e.g., vincristine, vinblastine, oxazolidinone, vinblastine, vinorelbine, paclitaxel, docetaxel, VP-16, and VM-26); antimetabolites (e.g., methotrexate with or without leucovorin, 5-fluorouracil with or without leucovorin, 5-fluorodeoxyuridine, 6-mercaptopurine, 6-thioguanine, gemcitabine, cytarabine, 5-azacytidine, hydroxyurea, deoxycoformycin, and fludarabine); podophyllotoxins (e.g., etoposide, irinotecan, and topotecan); and actinomycin D, dacarbazine (DTIC), mAMSA, procarbazine, altretinoin, pentamethylmelamine, L-asparaginase, and mitoxantrone. See, e.g., Cancer: Principles and Practice of Oncology, 4th ed., DeVita et al., eds., JB Lippincott Co., Philadelphia, Pa. (1993), relevant portions of which are incorporated herein by reference.

[0127] Other chemotherapeutic agents include those that act by the same general mechanism as described above. For example, agents that act by alkylating DNA, such as alkylating agents and nitrogen mustards, are considered chemotherapeutic agents. Agents that interfere with nucleotide synthesis, such as methotrexate, cytarabine, 6-mercaptopurine, 5-fluorouracil, and gemcitabine, are considered chemotherapeutic agents. Mitotic spindle toxins are considered chemotherapeutic agents, such as paclitaxel and vinblastine. Topoisomerase inhibitors that interfere with DNA replication (such as podophyllotoxins) are considered chemotherapeutic agents. Antibiotics that interfere with DNA synthesis by various mechanisms, such as doxorubicin, bleomycin, and mitomycin, are considered chemotherapeutic agents. Agents that aminocarbamylate amino acids (such as lomustine, carmustine) or agents that reduce asparagine reserves (such as asparaginase) are also considered chemotherapeutic agents. Merck Manual of Diagnosis and Therapy, 17th ed., Section 11, Hematology and Oncology, 144, Principles of Cancer Therapy, Table 144-2 (1999). Chemotherapeutic agents specifically include those that directly affect the same cellular processes affected by the above-mentioned chemotherapeutic agents.

[0128] In the context of an antibody mixture, a "cognate" HC as referred to herein is a HC that is known to pair with a particular LC to form a binding site for a particular antigen. For example, if a known full-length IgG antibody X binds to antigen X, then the antibody X HC is a cognate HC to the antibody X LC, and vice versa. Furthermore, if the mixture also contains antibody Y that binds to antigen Y, then the antibody Y HC is "non-cognate" with respect to the antibody X LC, and vice versa, and the antibody Y LC is "non-cognate" with respect to the antibody X HC, and vice versa.

[0129] The "complementarity determining region" (CDR) is a V H or V L Each V H and V L Contains three CDRs, referred to as CDR1, CDR2 and CDR3. CDRs form a loop on the antibody surface and are primarily responsible for determining the binding specificity of the antibody. The CDRs are interspersed between four more conservative framework regions (referred to as FR1, FR2, FR3 and FR4), as follows: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.

[0130] Kabat et al. HThe CDRs are positioned as follows: CDR1 at positions 31-35 (possible insertion numbers are 35A and 35B); CDR2 at positions 50-65 (possible insertion numbers are 52A-52C); and CDR3 at positions 95-102 (possible insertion numbers are 100A-100K). Kabat et al., supra, Section xvii, which is incorporated herein by reference. These positions of the CDRs are used herein, except for V H CDR1 is considered to include positions 26-35 in this article. Kabat et al. L The CDRs are located as follows: CDR1 at positions 24-34 (possible insertion numbers 27A-27F); CDR2 at positions 50-56; CDR3 at positions 89-97 (possible insertion numbers 95A-95F). Kabat et al., supra, Section xvii, which is incorporated herein by reference. V is used herein. L These positions of the CDRs.

[0131] If one treatment or drug is administered within the same short time frame as another treatment or drug (e.g., on the same day or within the same longer time frame), the two treatments / drugs are considered to be "simultaneously" administered. This longer time frame can include the following situations, such as one treatment / drug is administered once a week and the other is administered once every 4 days. Although the two treatments / drugs may never or rarely be administered on the same day, the two treatments / drugs are continuously administered within a common time period of weeks, months, or longer time periods. Similarly, if one drug is administered once a year and the other drug is administered once a week, if the weekly administered drug is administered during a year before and / or after the administration of the drug administered once a year, they are considered to be "simultaneously" administered. Therefore, the "simultaneous" administration of two treatments / drugs referred to herein includes the use of continuous treatment with two different treatments / drugs that are continued within a common time period.

[0132] Two or more antibodies are "different" as referred to herein if the amino acid sequences of all polypeptide chains contained in the two or more antibodies are not "identical" as referred to herein.

[0133] If two amino acid sequences can be encoded by the same DNA sequence, then the two sequences are "identical" as referred to herein. That is, amino acid sequences that differ only by post-translational modifications such as the elimination of carboxyl-terminal lysine or the cyclization of N-terminal glutamic acid or glutamine residues are "identical" as referred to herein.

[0134] Amino acid sequences are referred to herein as "different" if they have one or more amino acid substitutions, deletions or insertions relative to each other, but it should be noted that if the differences are caused only by post-translational modifications, i.e. if the amino acid sequences can be encoded by the same DNA sequence, such "different" amino acid sequences are not considered different.

[0135] The "Fc fragment", "Fc region" or "Fc portion" referred to herein essentially consists of the hinge domain (hinge), the second heavy chain constant domain (C H 2) and C H 3, although in some isotypes such as IgA or IgM it may also contain C H 3 downstream area.

[0136] The "heavy chain (HC)" referred to herein comprises at least V H , C H 1. Hinge, C H 2 and C H 3. A HC that includes all of these domains may also be referred to as a "full-length HC" or, in some embodiments, an "IgG HC". Some isotypes, such as IgA or IgM, may contain additional sequences, such as IgM C H The numbering system of Kabat et al. above is used for V H (See FIG1 ), and the EU system (Edelman et al., (1969), Proc. Natl. Acad. Sci. USA 63:78-85, which is incorporated herein by reference in its entirety) was used for C H 1. Hinge, C H 2 and C H 3. The use of these well-known numbering systems may result in differences between the actual amino acid position in the sequences disclosed herein and the number assigned to that position using the Kabat or Edelman numbering system. However, one skilled in the art can assign a Kabat or Edelman number to any particular position in the disclosed antibody sequences with reference to the knowledge in the art and the tables disclosed below, which show how Kabat or Edelman numbers can be assigned with reference to conserved features of antibody sequences that may be located in the disclosed sequences. Tables 1 and 2 below illustrate such numbering on a generalized HC sequence.

[0137] Table 1: Human V H consensus sequence of

[0138]

[0139] Table 1: This table shows the human V based on Kabat et al. (supra). HThe conserved amino acids of the amino acid sequence (I-III) are numbered according to Kabat et al., supra. Position numbers within the CDR are written in bold italics. With the exception of 82A-82C, position numbers followed by letters, such as 100A, may not necessarily be filled with amino acids due to the different lengths of the CDRs. H In the present invention, positions 82A-82C located in the framework region are always filled with amino acids. The single bold amino acid at a specific position represents a human V class I-III as described by Kabat et al. (supra). H At certain sites, when the amino acid at a given position is most often one or either of two amino acids, these amino acids are indicated in plain text.

[0140] Table 1 shows that there are a large number of conserved amino acids with conserved spacing, which allows any V H The sequence is aligned with the conserved amino acids spaced as above. Alternatively, alignment software can be used to compare the new sequence with known V H Sequences can be aligned, for example, in the International Immunogenetics (IMGT) Alignment software available on the Internet (e.g., IMGT / DomainGapAlign, which can be obtained at http: / / www.imgt.org, or CLUSTAL Omega (Sievers et al., (2011), Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega, Molecular Systems Biology 7(1):539).

[0141] Table 2 below shows an alignment of the human IgG Fc regions of the four human IgG subclasses, IgG1, IgG2, IgG3 and IgG4. The alignment shows the differences between these subclasses as well as the high degree of sequence conservation.

[0142] Table 2: Amino acid sequence of human IgG Fc region

[0143]

[0144] A "human" nucleotide or amino acid sequence, protein or antibody is a sequence or protein that naturally occurs in humans, or a sequence or protein that is identical to such a sequence or protein except for a small number of mutations or changes explained below. Many human nucleotide and amino acid sequences are reported, for example, in Kabat et al., supra, which illustrate the use of the term "human" in the art. The "human" amino acid sequence or antibody referred to herein may contain one or more insertions, deletions or substitutions relative to the naturally occurring sequence, provided that the "human" amino acid sequence contains no more than 10 insertions, deletions and / or substitutions of a single amino acid in every 100 amino acids. Similarly, a human nucleotide sequence does not contain more than 30 insertions, deletions and / or substitutions of a single nucleotide in every 300 nucleotides. In V H or V L In the specific case of an amino acid sequence (or a nucleotide sequence encoding such an amino acid sequence), it is expected that the CDRs are extremely variable, and in order to determine a specific V H or V L Whether or not the amino acid sequence (or its encoding nucleotide sequence) is a "human" sequence, the CDRs (or their encoding nucleotides) are not considered part of said sequence.

[0145] As used herein, a "heterodimer" is a protein dimer in which the two proteins in the dimer have different amino acid sequences. In the specific case of an IgG antibody having a heterodimeric HC / HC pair, the V sequences of the two different HCs in the heterodimeric pair are H The domains have different amino acid sequences.

[0146] "Humanized" antibodies as referred to herein are antibodies that are non-human, but have been transformed into humans as much as possible, while retaining binding properties similar to non-human antibodies, thereby hopefully reducing immunogenicity in humans. In general, this means that most or all of the framework regions of the constant and variable domains are human or near-human sequences, while the CDRs are derived from different organisms. However, simply transplanting CDRs from, for example, mouse antibodies into a human framework may not produce antibodies with the desired properties, and may require further modification to ensure the desired binding and stability properties. In recent years, various methods for simplifying and improving humanization results have been developed. See, e.g., Kurella and Gali (2014), Structure guided homology model based design and engineering of mouse antibodies for humanization, Bioinformation 10(4):180-186, and Choi et al., (2015), mAbs 7(6):1045-1057 (incorporated herein by reference in their entireties), and references cited therein.

[0147] The "IgG antibody" referred to herein comprises (1) two HCs, each of which comprises V H , C H 1. Hinge domain, C H 2 and C H 3, and (2) two light chains (LC), each LC containing V L and LC constant domain (C L ). The heavy chain of an IgG antibody is of the IgG isotype, e.g., IgG1, IgG2, IgG3, or IgG4. These domains are described, e.g., in Kabat et al., supra, at pages xv-xix and 647-699, which are also incorporated herein by reference. The above numbering system of Kabat et al. is used for V H and V L (See Figures 1 and 2), and the EU system (Edelman et al., (1969), Proc. Natl. Acad. Sci. USA 63:78-85, which is incorporated herein by reference in its entirety) was used for C L , C H 1. Hinge, C H 2 and C H 3.

[0148] "Inhibition" of the interaction between CCL1 and CCR8 as referred to herein can be measured using the chemotaxis assay described in the Examples below, in which the ability of anti-CCR8 antibodies to block CCL1-mediated chemotaxis in P815 cells stably transfected with full-length human CCR8 protein is measured. The IC values ​​of antibodies (or any class of molecules) that "inhibit" the interaction between CCL1 and CCR8 as referred to herein in the chemotaxis assay are as follows: 50 Less than 100 ng / ml, less than 90 ng / ml, less than 80 ng / ml, less than 70 ng / ml, less than 60 ng / ml, less than 50 ng / ml or less than 40 ng / ml.

[0149] "Inhibition" of the interaction between human programmed cell death protein 1 (hPD1) and human programmed cell death protein 1 ligand 1 (hPDL1) can be measured as described in Example 7 on page 69, lines 3-30, Table 15 on page 70, and Figure 13 (all of which are incorporated herein by reference) in WO 2018 / 089293. The PD1 dual reporter assay system relies on the fact that in T cells induced by anti-CD3 antibody activation, the interaction of PDL1 with PD1 expressed on T cells inhibits the transcription of the nuclear factor of activated T cells (NFAT) gene from the promoter. The T cells used in the assay express hPD1 on their cell surface and contain a luciferase gene whose expression is driven by the NFAT promoter. If hPD1 on the cell surface is bound by hPDL1, the production of luciferase will be inhibited. This inhibition can be reversed when anti-hPD1 antibodies prevent the binding of hPDL1 to hPD1.

[0150] The assay can be performed as follows. CHO-K1 cells expressing hPDL1 and anti-CD3 antibodies (see e.g. CCL-61 TM ) (in 50 μL of F-12 medium containing 10% fetal bovine serum (FBS) (see e.g. 30-2004TM), 4×10 per well 4 Cells) were distributed into half-area 96-well plates (Costar, 3688) and incubated overnight. The next day, in a separate plate, starting at a concentration of 68 nM, in assay medium (Roswell Park Memorial Institute (RPMI) 1640 medium containing 2% FBS (see, e.g. 30-2001 TM) were prepared in duplicate. The medium was then removed from each well containing CHO-K1 cells and replaced with 20 μL of medium from the well containing the diluted test antibody and 20 μL of Jurkat T cells (4×10 4 The plates were incubated at 37°C in 5% CO2 for 6 hours. After incubation, 38 μL of Bio-Glo was added to each well according to the manufacturer's instructions. TM Reagent (Promega catalog number G7941). Luciferase activity was read on an EnVision multilabel plate reader (PerkinElmer). Data can be plotted as relative luminescence units (RLU) and analyzed using GraphPad Prism software (GraphPad, Inc., La Jolla, CA, USA) to determine IC 50 The IC values ​​of antibodies that “inhibit” the interaction between hPD1 and hPDL1 in the assay are 50 Not exceeding the IC of anti-hPD1Ab9 50 20, 15, 10 or 5 times of.

[0151] "Inhibition" of the interaction of human CTLA4 (hCTLA4) with human B lymphocyte activation antigen B7-1 (hB7-1) and / or human B lymphocyte activation antigen B7-2 (hB7-2) can be determined as described in Example 4, page 66, line 17 to page 67, line 17, Table 12 on page 67, and Figure 11 of WO 2018 / 089293 (all of which are incorporated herein by reference). In short, the functional effect of anti-CTLA4 antibodies on CTLA4 activity can be assessed using the CTLA4 dual cell reporter assay (Promega CS186907). In this assay, anti-CD3 activation of Jurkat cells (which are human cells expressing a luciferase reporter gene driven by the IL-2 promoter) induces luciferase production, which can be inhibited by binding of hB7-1 or hB7-2 (expressed on added Raji cells) to hCTLA4 expressed on the same Jurkat cells. Anti-CTLA4 antibodies that bind to hCTLA4 and inhibit or block the binding of hB7-1 or hB7-2 can remove the inhibitory signal that blocks the IL-2 pathway, thereby restoring the luciferase signal in the dual cell reporter system.

[0152] As briefly described below, the assay can be performed essentially according to the manufacturer's instructions. Engineered Jurkat T cells expressing CTLA4 are distributed in assay medium (RPMI 1640 medium containing 10% FBS) into half-area 96-well plates (Costar, catalog number 3688) with 5×10 cells / well in 15 μL. 4 In separate microtiter plates, serial dilutions of each test antibody were prepared. Then, two 15 μL additions were added to each well containing Jurkat T cells, one containing the test antibody dilution and the other containing 5 × 10 4 Raji cells (which express hB7-1 and hB7-2) and anti-CD3 antibodies. The microtiter plates were incubated at 37°C under 5% CO2 for 16 hours. After incubation, 40 μL of Bio-Glo TM Reagent (Promega, catalog number G7941). Luciferase activity was detected using an EnVision 2103 multilabel plate reader (PerkinElmer). Data were plotted as RLU graphs and analyzed using GraphPad Prism software to determine IC 50 If an antibody has an IC 50 Does not exceed the IC of anti-CTLA4 antibody 7A4 50 If the antibody "inhibits" the interaction of hCTLA4 with hB7-1 / hB7-2 by 20, 15, 10 or 5 times that of hCTLA4.

[0153] "Inhibitor" as referred to herein is similar to "antagonist" as defined above, with the difference that it refers to a small molecule (as opposed to a protein or polynucleotide), while an antagonist is a more general term for any type of molecule. For example, "tyrosine kinase inhibitor" refers to a small molecule that antagonizes tyrosine kinase. In addition, "targeted inhibitor" refers to an inhibitor that interferes with a specific target (i.e., a specific biological pathway or a specific protein). In order to avoid any confusion, this association of the term "inhibitor" with a small molecule does not extend to the verb "inhibit" or the noun "inhibit". For example, as demonstrated herein, macromolecules such as antibodies can inhibit the interaction of, for example, CCL1 and CCL8. Similar methods can be used to prove that a targeted inhibitor "targets" a specific interaction or pathway. In addition, the "inhibition" of an interaction is not necessarily mediated by a small molecule to become the "inhibition" referred to herein.

[0154] The "light chain (LC)" referred to herein comprises V L and C L , which can be κ(C L κ) or λ(C LThese domains, including their exemplary amino acid sequences, are described, for example, in Kabat et al., supra, at pages xiii-lix, 103-309, and 647-660, which are incorporated herein by reference. L The numbering system is that described in Kabat et al., supra, for C L The EU numbering system is the numbering system described in Edelman et al., supra. Tables 3 and 4 below illustrate the application of these systems to various light chain sequences. One skilled in the art can use such information to assign Kabat or Edelman numbers to specific positions in the sequences disclosed herein.

[0155] Table 3: Human V L consensus sequence of

[0156]

[0157] Table 3: Numbering according to Kabat et al. (supra). Bold italic numbers indicate the position of the CDR. Position numbers followed by letters, such as 27A, are not necessarily filled with amino acids due to the different lengths of the CDRs. The invariant residues of all human light chains in Kabat et al. (supra) are shown in bold letters, indicating the amino acid found at that position. At selected sites, one or two amino acids that are common at that site are shown in plain text. In addition, many other amino acids are present in the κ or λ V L Some subgroups of V are invariant or highly conserved, which can help to classify specific amino acid sequences as V L The sites selected for alteration in PCT / US2018 / 089293 or PCT / US2017 / 030676 are used Bold Underline express.

[0158] Table 4: C L Consensus sequence and numbering

[0159]

[0160] Table 4: Numbering is according to Edelman et al. (supra), which is consistent with Kabat et al. (supra) for C L The amino acids in bold below the numbers are the kappa and lambda C residues from various species according to Kabat et al. (supra). LThe "invariant" residues of the alignment of the two. As shown at selected positions (131, 160, 162, 174, 176 and 178), the conserved amino acids reported in Kabat et al. (supra) in 10 human kappa chains (above) and 28 human lambda chains (below) are shown in plain text. In the case of either of the two different amino acids at one of these positions, the more common amino acid is shown before the less common amino acid, e.g., A / M. Bold Underline Numbers indicate the sites that were altered as reported in PCT / US2018 / 089293 or PCT / US2017 / 030676. In addition, many other amino acids were altered in C L κ or C L The λ domains are invariant or highly conserved in some subgroups, which can help to classify specific amino acid sequences as C L .

[0161] In the context of an antibody mixture, the "main species" of an antibody referred to herein is a specific antibody that accounts for at least 10% of the total amount of antibodies in the mixture. In order to determine how many main species there are in an antibody mixture, a low pH CEX chromatography as described in lines 9-30 on page 92 of WO2017 / 205014 and Figure 14 (the portion of WO 2017 / 205914 is incorporated herein by reference) can be performed. This method is described by Chen et al., (2010), Protein Science, 19: 1191-1204, which is incorporated herein by reference in its entirety. In short, it utilizes Thermo PROPAC TM WCX-10 weak CEX column, 4×250 mm, preceded by a 50 mm guard column (PROPAC TM WCX-10G) and using a Waters Alliance 2695 high performance liquid chromatography (HPLC) system. The chromatogram was run with a linear gradient from 100% buffer A (20 mM sodium acetate, pH 5.2) to 100% buffer B (20 mM sodium acetate and 250 mM sodium chloride, pH 5.2) in 30 minutes. The column can be washed with high salt (1 M sodium chloride) and re-equilibrated to the starting conditions of buffer A. The antibody can be detected in the column effluent by absorbance at 214 nm. The relative amount of the detected peak can be measured using EMPOWER TM Low pH CEX can distinguish different full-length antibody species and can be used to quantify the relative amount of a specific antibody species in a mixture.

[0162] As referred to herein, a "minor species" of an antibody within an antibody mixture comprises less than 10% of the total amount of antibodies in the mixture. This can be determined by low pH CEX chromatography as described in the definition of "major species".

[0163] The terms "nucleic acid" and "polynucleotide" are used interchangeably herein.

[0164] "Primate" nucleotide or amino acid sequence or protein is a sequence or protein naturally present in a nucleic acid or protein found in a primate, or a sequence or protein identical to such a sequence or protein except for the minor changes described below. Primates include many families of animals, including but not limited to prosimians (including lemurs), New World monkeys, chimpanzees, humans, gorillas, orangutans, gibbons, and Old World monkeys. Specific primate species include but are not limited to Homo sapiens (Homo sapiens), Macaca mulata (rhesus monkey), Macaca fascicularis (crab-eating monkey), and Pan troglodytes (chimpanzee), etc. Many primate nucleotide and amino acid sequences are known in the art, such as those reported in Kabat et al. above. Generally, the "primate" amino acid sequence referred to herein may contain one or more insertions, deletions, or substitutions relative to a naturally occurring primate sequence, provided that the "primate" amino acid sequence has no more than 10 single amino acid insertions, deletions, and / or substitutions per 100 amino acids. Similarly, the primate nucleotide sequence has no more than 30 single nucleotide insertions, deletions and / or substitutions per 300 nucleotides relative to the naturally occurring primate sequence. H or V L In certain cases of sequence, CDRs are expected to be extremely variable and in order to determine the specific V H or V L Whether or not an amino acid sequence (or a nucleotide sequence encoding it) is a "primate" sequence, the CDRs (or the nucleotides encoding them) are not considered part of that sequence.

[0165] As used herein, a "signal peptide" is an amino acid sequence on a protein, in many cases an amino-terminal sequence, which in combination with a signal recognition particle targets the protein to the endoplasmic reticulum in eukaryotic cells (and possibly to the cell surface) or the plasma membrane in prokaryotic cells. See, for example, Hegde and Bernstein, (2006), Trends in Biochemical Sciences 31(6):563-571. Although the primary sequence of a signal peptide is somewhat variable, many sequences are known in the art. The N-terminal signal peptide is usually cleaved from the protein in the mature form of the protein.

[0166] As used herein, a "targeted biologic" is a protein that can affect some aspect of a cell's biological state by interacting with another specific molecule (which can be a protein). For example, a "targeted biologic" may affect a cell's ability to survive, proliferate, produce a specific cytokine or protein, etc. For example, the anti-CCR8 antibodies described herein are "targeted biologics" because they interact with CCR8, thereby producing many of the biological effects described in the Examples below.

[0167] Likewise, a "targeted inhibitor" as referred to herein is a small molecule that can affect a certain aspect of a cell's biological state by interacting with a specific cellular molecule (which can be a protein). For example, a "tyrosine kinase inhibitor" is a small molecule that affects the activity of a tyrosine kinase (which can affect various cellular functions) by interacting with the tyrosine kinase.

[0168] "Treatment" of a particular disease or condition as referred to herein refers to a course of action that may include the administration of one or more antibodies, polynucleotides encoding one or more antibodies, and / or one or more other molecules, resulting in alleviation of one or more symptoms of the disease or condition or reduction or interruption of its expected progression in a human patient, an animal model system believed to reflect the disease or condition, or an in vitro cell-level assay that is believed to reflect the disease or condition. This can be determined by objective measurement of symptoms in humans or animals or by measurement of various parameters in cell-level assays, such as the production of one or more cytokines such as IFNγ, cell proliferation, cell death, etc. For example, for cancer "treatment", the treatment may result in a reduction in tumor volume in a human or animal model system, a lack of expected tumor metastasis in a human or animal model system, an extension of survival time or progression-free survival or disease-free survival in humans or animals with cancer. Cancer treatment may also result in exponential increases in cellular assays indicative of activation of certain aspects of the immune system, such as phagocytosis of cancer cells by macrophages, proliferation of T cells, and / or increased production of cytokines (e.g., type I IFN, IFNγ, and / or IL-2) by one or more cell types that play a role in the immune system.

[0169] Anti-CCR8 antibody and mixture containing anti-CCR8 antibody

[0170] In one aspect, the present invention provides variable domains of anti-CCR8 monoclonal antibodies (Mabs) having unique amino acid sequences, including those sequences set forth in the sequence table. As shown in the examples below, these monoclonal antibodies (Mabs) can bind to the antigen encoded by the CCR8 allele in humans and cynomolgus monkeys, i.e., the CCR8 protein, and can inhibit the interaction between CCL and CCR8. In one aspect, these antibodies can be, for example, human, humanized or primate IgG antibodies, which can be IgG1, IgG2, IgG3 or IgG4 antibodies. In one aspect, the antibody is a human or humanized IgG1 antibody. In a specific embodiment, V H and V L The amino acid sequence is selected from:

[0171] (1) V of anti-CCR8Mab 953 antibody H comprising the amino acid sequence of SEQ ID NO: 3, and V of the anti-CCR8Mab 953 antibody L An amino acid sequence comprising SEQ ID NO: 4;

[0172] (2) V of anti-CCR8Mab 1047 H comprising the amino acid sequence of SEQ ID NO: 13, and V L An amino acid sequence comprising SEQ ID NO: 14;

[0173] (3) V of anti-CCR8Mab 1187 H The amino acid sequence of SEQ ID NO: 23 is included, and V L comprising the amino acid sequence of SEQ ID NO: 24; and

[0174] (4) V of anti-CCR8Mab 1434 antibody H The anti-CCR8 antibodies described herein may comprise V L and V H Both, but may lack some or all of the IgG constant domains. For example, the anti-CCR8 antibodies described herein may be scFv, scFvFc or Antibodies and many possible forms. In some embodiments, the anti-CCR8 antibodies described herein may be bispecific antibodies that bind to CCR8 and another antigen, such as a cancer antigen such as HER2, EGFR, CEA, CD123, B7H4, B7H3, CD20, CD37, CD38, tight junction protein 18.2, GPC3 or BCMA. In some embodiments, the anti-CCR8 antibodies described herein may be bispecific antibodies that bind to CCR8 and checkpoint molecules such as PD1, PDL1, CTLA4 or GITR. In some embodiments, the anti-CCR8 antibodies described herein may be bispecific antibodies that bind to CCR8 and immunostimulatory molecules such as CD27, CD40, OX40, GITR or 4-1BB.

[0175] In one aspect, the V of the anti-CCR8 antibodies described herein is H May contain V H CDR1, V H CDR2 and V H CDR3, which comprises:

[0176] Anti-CCR8Mab 953V H CDR1, CDR2, and CDR3 have the amino acid sequences of SEQ ID NOs: 5, 6, and 7, respectively;

[0177] Anti-CCR8Mab 1047V H CDR1, CDR2, and CDR3 have the amino acid sequences of SEQ ID NOs: 15, 16, and 17, respectively;

[0178] The anti-CCR8 Mab 1187 VH CDR1, CDR2 and CDR3 have the amino acid sequences of SEQ ID NOs: 25, 26 and 27, respectively; and / or

[0179] The anti-CCR8 Mab 1434 VH CDR1, CDR2 and CDR3 have the amino acid sequences of SEQ ID NOs: 35, 36 and 37, respectively. H The antibody can bind to a protein comprising the amino-terminal extracellular domain of CCR8, such as a recombinant human CCR8 antigen, and its K D No more than 1nM (10 -9 M), 0.9nM (0.9×10 -9 M), 0.8nM (0.8×10 -9 M) or 0.7 nM (0.7×10 -9M). Alternatively or in addition, such antibodies may bind to a protein comprising the amino-terminal extracellular domain of CCR8, such as a recombinant human CCR8 antigen, whose K A At least 1×10 -6 , 1.1×10 -6 , 1.2×10 -6 , 1.3×10 -6 , 1.4×10 -6 , 1.5×10 -6 , 1.6×10 -6 , 1.7×10 -6 , 1.8×10 -6 or 1.9×10 -6 Alternatively or additionally, such anti-CCR8 antibodies may bind to various allelic versions of human or cynomolgus CCR8. Alternatively or additionally, such antibodies may have an IC of less than 100 ng / ml, less than 90 ng / ml, less than 80 ng / ml, less than 70 ng / ml, less than 60 ng / ml, less than 50 ng / ml or less than 40 ng / ml in the chemotaxis assays described above and below. 50 The assay measures the ability of the anti-CCR8 antibodies to block CCL1-mediated chemotaxis in P815 cells stably transfected with full-length human CCR8 protein.

[0180] Furthermore, in certain embodiments, as described above, the V of the anti-CCR8 antibodies described herein is H It may comprise the amino acid sequence of SEQ ID NO: 3, 13, 23 or 33. In some embodiments, the V of the anti-CCR8 antibody described herein is H Slightly altered versions of these sequences may be included. In some embodiments, such alterations occur only in the framework regions and not in the CDRs. H It may comprise an amino acid sequence encoded by a polynucleotide corresponding to SEQ ID NO: 11, 21, 31 or 41, but the amino acid sequence may differ from the amino acid sequence due to one or more alterations or post-translational modifications. H Can comprise one or more changes relative to any of SEQ ID NO: 3, 13, 23 or 33, which changes can be amino acid substitutions. In some embodiments, V H The amino acid sequence of SEQ ID NO: 3, 13, 23 or 33 or an altered version of these sequences as described above comprising one or more alterations may contain no more than 6, 5, 4, 3, 2 or 1 amino acid changes relative to SEQ ID NO: 3, 13, 23 or 33. HThe antibody can bind to a protein comprising the amino terminal extracellular domain of CCR8, such as a recombinant human CCR8 antigen, and its K D No more than 1nM (10 -9 M), 0.9nM (0.9×10 -9 M), 0.8nM (0.8×10 -9 M) or 0.7 nM (0.7×10 -9 M). Alternatively or in addition, such antibodies may bind to a protein comprising the amino-terminal extracellular domain of CCR8, such as a recombinant human CCR8 antigen, whose K A At least 1×10 -6 , 1.1×10 -6 , 1.2×10 -6 , 1.3×10 -6 , 1.4×10 -6 , 1.5×10 -6 , 1.6×10 -6 , 1.7×10 -6 , 1.8×10 -6 or 1.9×10 -6 Alternatively or additionally, such anti-CCR8 antibodies may bind to various allelic versions of human and / or cynomolgus monkey CCR8. Alternatively or additionally, such antibodies may inhibit the interaction between CCL1 and CCR8. Alternatively or additionally, such antibodies may have an IC of less than 100 ng / ml, less than 90 ng / ml, less than 80 ng / ml, less than 70 ng / ml, less than 60 ng / ml, less than 50 ng / ml, or less than 40 ng / ml in the chemotaxis assays described above and below. 50 The assay measures the ability of the anti-CCR8 antibodies to block CCL1-mediated chemotaxis in P815 cells stably transfected with full-length human CCR8 protein.

[0181] Likewise, the V of the anti-CCR8 antibodies described herein L Can contain V L CDR1, CDR2 and CDR3, which comprise:

[0182] Mab 953V L CDR1, CDR2, and CDR3 have the amino acid sequences of SEQ ID NOs: 8, 9, and 10, respectively;

[0183] Mab 1047V L CDR1, CDR2, and CDR3 have the amino acid sequences of SEQ ID NOs: 18, 19, and 20, respectively;

[0184] Mab 1187V LCDR1, CDR2 and CDR3 have the amino acid sequences of SEQ ID NOs: 28, 29 and 30, respectively; and / or

[0185] Mab 1434V L CDR1, CDR2 and CDR3 have the amino acid sequences of SEQ ID NOs: 38, 39 and 40, respectively. L The antibody can bind to a protein comprising the amino-terminal extracellular domain of CCR8, such as a recombinant human CCR8 antigen, and its K D No more than 1nM (10 -9 M), 0.9nM (0.9×10 -9 M), 0.8nM (0.8×10 -9 M) or 0.7 nM (0.7×10 -9 M). Alternatively or in addition, such antibodies may bind to a protein comprising the amino-terminal extracellular domain of CCR8, such as a recombinant human CCR8 antigen, whose K A At least 1×10 -6 , 1.1×10 -6 , 1.2×10 -6 , 1.3×10 -6 , 1.4×10 -6 , 1.5×10 -6 , 1.6×10 -6 , 1.7×10 -6 , 1.8×10 -6 or 1.9×10 -6 Alternatively or additionally, such anti-CCR8 antibodies may bind to various allelic versions of human and / or cynomolgus monkey CCR8. Alternatively or additionally, such antibodies may inhibit the interaction between CCL1 and CCR8. Alternatively or additionally, such antibodies may have an IC of less than 100 ng / ml in the chemotaxis assay described above and below. 50 The assay measures the ability of the anti-CCR8 antibodies to block CCL1-mediated chemotaxis in P815 cells stably transfected with full-length human CCR8 protein.

[0186] Furthermore, in certain embodiments, as described above, the V of the anti-CCR8 antibodies described herein is L The antibodies may contain amino acid sequences of SEQ ID NOs: 4, 14, 24, 34, etc. In some embodiments, such antibodies may contain altered versions of these sequences. In some embodiments, such alterations occur only in the framework regions and not in the CDRs. In some embodiments, such V LIt may comprise an amino acid sequence encoded by a polynucleotide corresponding to SEQ ID NO: 12, 22, 32 or 42, but the amino acid sequence may differ from one of these amino acid sequences due to one or more alterations or post-translational modifications. L Can contain one or more changes relative to SEQ ID NO: 4, 14, 24 or 34, and the changes can be amino acid substitutions. In some embodiments, V L The amino acid sequence of SEQ ID NO: 4, 14, 24, or 34 may contain no more than 6, 5, 4, 3, 2, or 1 amino acid changes. These amino acid changes may be substitutions, and / or may be partner-directed changes as described in U.S. Pat. No. 11,124,570, etc. A V comprising an amino acid sequence of SEQ ID NO: 4, 14, 24, or 34, or an altered version of these sequences as described above containing one or more changes L The antibody can bind to a protein comprising the amino terminal extracellular domain of CCR8, such as a recombinant human CCR8 antigen, and its K D No more than 1nM (10 -9 M), 0.9nM (0.9×10 -9 M), 0.8nM (0.8×10 -9 M) or 0.7 nM (0.7×10 -9 M). Alternatively or in addition, such antibodies may bind to a protein comprising the amino-terminal extracellular domain of CCR8, such as a recombinant human CCR8 antigen, whose K A At least 1×10 -6 , 1.1×10 -6 , 1.2×10 -6 , 1.3×10 -6 , 1.4×10 -6 , 1.5×10 -6 , 1.6×10 -6 , 1.7×10 -6 , 1.8×10 -6 or 1.9×10 -6 Alternatively or additionally, such anti-CCR8 antibodies may bind to various allelic versions of human and / or cynomolgus monkey CCR8. Alternatively or additionally, such antibodies may inhibit the interaction between CCL1 and CCR8. Alternatively or additionally, such antibodies may have an IC of less than 100 ng / ml, less than 90 ng / ml, less than 80 ng / ml, less than 70 ng / ml, less than 60 ng / ml, less than 50 ng / ml or less than 40 ng / ml in the chemotaxis assay described above and below. 50The assay measures the ability of the anti-CCR8 antibodies to block CCL1-mediated chemotaxis in P815 cells stably transfected with full-length human CCR8 protein.

[0187] In another aspect, the anti-CCR8 antibody may comprise V H CDR1, V H CDR2, V H CDR3, V L CDR1, V L CDR2 and V L CDR3, each having an amino acid sequence selected from the group consisting of:

[0188] Anti-CCR8Mab 953V H CDR1, CDR2 and CDR3 have the amino acid sequences of SEQ ID NOs: 5, 6 and 7, respectively, and Mab 953V L CDR1, CDR2, and CDR3 have the amino acid sequences of SEQ ID NOs: 8, 9, and 10, respectively;

[0189] Anti-CCR8Mab 1047V H CDR1, CDR2 and CDR3 have the amino acid sequences of SEQ ID NOs: 15, 16 and 17, respectively, and Mab 1047V L CDR1, CDR2, and CDR3 have the amino acid sequences of SEQ ID NOs: 18, 19, and 20, respectively;

[0190] anti-CCR8 Mab 1187 VH CDR1, CDR2 and CDR3 have the amino acid sequences of SEQ ID NOs: 25, 26 and 27, respectively, and Mab 1187 VL CDR1, CDR2 and CDR3 have the amino acid sequences of SEQ ID NOs: 28, 29 and 30, respectively;

[0191] The anti-CCR8 Mab 1434 VH CDR1, CDR2 and CDR3 have the amino acid sequences of SEQ ID NOs: 35, 36 and 37, respectively, and Mab 1434 VL CDR1, CDR2 and CDR3 have the amino acid sequences of SEQ ID NOs: 38, 39 and 40, respectively.

[0192] An antibody comprising any of these CDR sequence groups can bind to a protein comprising the amino-terminal extracellular domain of CCR8, such as a recombinant human CCR8 antigen, wherein the D No more than 1nM (10 -9 M), 0.9nM (0.9×10 -9M), 0.8nM (0.8×10 -9 M) or 0.7 nM (0.7×10 -9 M). Alternatively or in addition, such antibodies may bind to a protein comprising the amino-terminal extracellular domain of CCR8, such as a recombinant human CCR8 antigen, whose K A At least 1×10 -6 , 1.1×10 -6 , 1.2×10 -6 , 1.3×10 -6 , 1.4×10 -6 , 1.5×10 -6 , 1.6×10 -6 , 1.7×10 -6 , 1.8×10 -6 or 1.9×10 -6 Alternatively or additionally, such anti-CCR8 antibodies may bind to various allelic versions of human and / or cynomolgus monkey CCR8. Alternatively or additionally, such antibodies may inhibit the interaction between CCL1 and CCR8. Alternatively or additionally, such antibodies may have an IC of less than 100 ng / ml, less than 90 ng / ml, less than 80 ng / ml, less than 70 ng / ml, less than 60 ng / ml, less than 50 ng / ml or less than 40 ng / ml in the chemotaxis assay described above and below. 50 The assay measures the ability of the anti-CCR8 antibodies to block CCL1-mediated chemotaxis in P815 cells stably transfected with full-length human CCR8 protein.

[0193] In another aspect, the V of the anti-CCR8 antibodies described herein is H and V L may respectively comprise SEQ ID NO: 3 (V H ) and 4(V L )、13(V H ) and 14(V L )、23(V H ) and 24(V L ) and 33(V H ) and 34(V L ). In some embodiments, V in one of the two sequences is H and / or V L can be changed. For example, the V H and / or V L can be compared to the V just listed above H and / or V L The sequence contains one or more changes. H and / or V LThe amino acid sequences listed above may contain no more than 6, 5, 4, 3, 2 or 1 changes. H and V L Any one of them can also change the V H and V L Both. Optionally, the alteration may be a substitution. An antibody comprising the amino acid sequence listed immediately above or an altered version thereof as described above may bind to a protein comprising the amino-terminal extracellular domain of CCR8, such as a recombinant human CCR8 antigen, wherein K D No more than 1nM (10 -9 M), 0.9nM (0.9×10 -9 M), 0.8nM (0.8×10 -9 M) or 0.7 nM (0.7×10 -9 M). Alternatively or in addition, such antibodies may bind to a protein comprising the amino-terminal extracellular domain of CCR8, such as a recombinant human CCR8 antigen, whose K A At least 1×10 -6 , 1.1×10 -6 , 1.2×10 -6 , 1.3×10 -6 , 1.4×10 -6 , 1.5×10 -6 , 1.6×10 -6 , 1.7×10 -6 , 1.8×10 -6 or 1.9×10 -6 Alternatively or additionally, such anti-CCR8 antibodies may bind to various allelic versions of human and / or cynomolgus monkey CCR8. Alternatively or additionally, such antibodies may inhibit the interaction between CCL1 and CCR8. Alternatively or additionally, such antibodies may have an IC of less than 100 ng / ml, less than 90 ng / ml, less than 80 ng / ml, less than 70 ng / ml, less than 60 ng / ml, less than 50 ng / ml or less than 40 ng / ml in the chemotaxis assay described above and below. 50 The assay measures the ability of the anti-CCR8 antibodies to block CCL1-mediated chemotaxis in P815 cells stably transfected with full-length human CCR8 protein.

[0194] In some embodiments, described herein are mixtures comprising an anti-CCR8 monoclonal antibody (Mab) described herein and a targeted inhibitor (as defined above) or a second antibody that binds to a second antigen. The second antigen can be a protein, such as (1) a cancer antigen, such as V-ERB-B2 avian erythroblastic leukemia viral oncogene homolog 2 (referred to herein as HER2, also known as ERBB2, neuroblastoma or glioblastoma-derived factor (NGL), NEU, tyrosine kinase-type cell surface receptor HER2 (TKR1)), epidermal growth factor receptor (referred to herein as EGFR; also known as V-ERB-B avian erythroblastic leukemia viral oncogene homolog, oncogene ERBB, ERBB1, HER1). or species-specific antigen 7 (SA7)), EGFRvIII, CEA, CD123, B7H4, B7H3, EpCAM, CD19, CD20, CD37, CD38, tight junction protein 18.2, GPC3 or BCMA, etc., (2) immune checkpoint molecules, such as PD1, PDL1, CTLA4 or GITR, etc., or (3) proteins expressed on cells that inhibit immune responses (such as myeloid-derived suppressor cells (MDSC) or regulatory T cells (Treg)), including, for example, CSF-1R. In addition, the second antibody can be an agonist antibody that binds to a second antigen such as CD27, CD40, OX40, GITR or 4-1BB. Similarly, as defined above, the targeted inhibitor can be targeted to one of the second antigens listed above and other possible targets. As explained below, such an antibody mixture or a mixture of an anti-CCR8 antibody and a targeted inhibitor can have improved clinical efficacy compared to any of the therapeutic agents alone in the mixture.

[0195] In another embodiment, the anti-CCR8 antibodies of the invention can be combined with an antibody cocktail, such as the checkpoint inhibitor PSB205 MabPair or a bispecific antibody.

[0196] Many anti-PD1 antibodies are disclosed in international applications WO 2018 / 089293 and related US11,124,570. The portions of WO2018 / 089293 and US11,124,570 containing descriptions of these antibodies and their properties and descriptions of methods for making and using these antibodies are incorporated herein by reference in their entirety. These portions of WO 2018 / 089293 include the following: pages 48-54; sequence listing; examples (pages 61-78); and Figures 1-22 and brief descriptions of these figures, all of which are incorporated herein by reference. These portions of U.S. application publication US11,124,570 include the following: Examples 2 and 6-13 and Figures 1-22, all of which are incorporated herein by reference.

[0197] The Vs of exemplary anti-human PD1 (anti-hPD1) antibodies are provided in the cited patents. H and V L In some embodiments, the amino acid sequence of V in one of the antibodies just listed above can be changed. H and / or V L For example, V H and / or V L can be relative to V in one of the antibodies H and / or V L The sequence contains one or more changes. H and / or V L No more than 6, 5, 4, 3, 2 or 1 changes may be included relative to the sequence in one of the antibodies listed immediately above. More specifically, the V H and V L In any of the above, it is also possible to change only the V H Or just change the V L Optionally, the change may be a substitution. H and V L The sequences or altered versions thereof as described just above can constitute antibodies that can inhibit the interaction between PD1 and PDL1 as defined above.

[0198] V sequences of exemplary anti-human CTLA4 (anti-hCTLA4) antibodies are provided in U.S. Pat. No. 11,124,570. H and V L The amino acid sequence of V is derived from H and V L The names of exemplary anti-CTLA4 antibodies can be selected from: anti-hCTLA4Ab1E1, anti-hCTLA4Ab2F1, anti-hCTLA4Ab3G1, anti-hCTLA4Ab4H1, anti-hCTLA4Ab5B2, anti-hCTLA4Ab6E3, anti-hCTLA4Ab7A4, anti-hCTLA4Ab8B4, anti-hCTLA4Ab9C4, anti-hCTLA4Ab10D4, anti-hCTLA4Ab11F4 and anti-hCTLA4Ab12G4, etc. In some embodiments, the V in these antibodies listed just above can be changed. H and / or V L For example, V H and / or V L can be relative to V in one of the antibodies H and / or V L The sequence contains one or more changes. H and / or VL No more than 6, 5, 4, 3, 2 or 1 changes may be included relative to the sequence in one of the antibodies listed immediately above. More specifically, the V H and V L In any of the above, it is also possible to change only the V H or V L Optionally, the alteration may be a substitution as defined above and exemplified in, for example, U.S. Pat. No. 11,124,570. H and V L The sequences or altered versions thereof as described immediately above can constitute antibodies capable of inhibiting the interaction of hCTLA4 with hB7-1 / hB7-2 as defined above.

[0199] In one aspect, the anti-CCR8 antibodies described herein can bind to human and / or cynomolgus monkey versions of CCR8. In some embodiments, the anti-CCR8 antibodies can be human, humanized, chimeric, or primate IgG antibodies, which can be IgG1, IgG2, IgG3, or IgG4 antibodies. In one embodiment, the anti-CCR8 antibodies can be human or humanized IgG1 antibodies. The anti-CCR8 antibodies can be part of a bispecific antibody that binds to CCR8 and another antigen. The anti-CCR8 antibodies can also have different formats, such as scFv, scFv-Fc, Single domain antibodies, bispecific antibodies, Fab-scFv, DVD-IgG, IgG(H)-scFv, nanobodies, nanobodies-HAS, diabodies, DARTs, TandAbs, scDiabodies, minibodies, minibodies, etc. See, e.g., Spiess et al., (2015), Molecular Immunology 67:95-106.

[0200] Similarly, the second antibody in the antibody mixture (i.e., an antibody other than the anti-CCR8 antibody) can bind to the human and / or cynomolgus monkey version of the second antigen. In one aspect, the second antibody can be a human, humanized, or primate IgG antibody, which can be an IgG1, IgG2, IgG3, or IgG4 antibody. The second antibody can also have different formats, such as scFv, scFv-Fc, Single domain antibody, bispecific antibody, Fab-scFv, DVD-IgG, IgG (H) -scFv, nanobody, nanobody-HAS, diabody, DART, TandAb, scDiabody, minibody, minibody, etc. See, for example, Spiess et al., (2015), Molecular Immunology 67: 95-106. In addition, the second antibody or a portion thereof, such as VH and / or V L , can be part of a bispecific antibody that also binds to CCR8.

[0201] The bispecific antibody comprising an anti-CCR8 antibody and a second antibody that binds to a second antigen can comprise any anti-CCR8 antibody described above and below and a second antibody that binds to, for example, the following antigens: (1) cancer antigens, such as V-ERB-B2 avian erythroblastic leukemia virus oncogene homolog 2 (referred to herein as HER2, also known as ERBB2, neuroblastoma or glioblastoma-derived factor (NGL), NEU, tyrosine kinase-type cell surface receptor HER2 (TKR1)), epidermal growth factor receptor (referred to herein as EGFR; also known as V-ERB-B avian erythroblastic leukemia virus Oncogene homologs, oncogenes ERBB, ERBB1, HER1 or species-specific antigen 7 (SA7)), EGFRvIII, CEA, CD123, B7H4, B7H3, EpCAM, CD19, CD20, CD37, CD38, tight junction protein 18.2, GPC3 or BCMA, etc., (2) immune checkpoint molecules, such as PD1, PDL1, CTLA4 or GITR, etc., or (3) proteins expressed on cells that inhibit immune responses (such as myeloid-derived suppressor cells (MDSC) or regulatory T cells (Treg)), including, for example, CSF-1R. In addition, the second antibody can be an agonist antibody that binds to a second antigen such as CD27, CD40, OX40, GITR or 4-1BB. Such bispecific antibodies can include a single variable domain or V domain from both the anti-CCR8 antibody and the second antibody. H and V L Both. Alternatively, a bispecific antibody may comprise one variable domain from one antibody and two variable domains from another antibody. As discussed above, a bispecific antibody may have any of a variety of forms and may be an IgG antibody comprising intact HC and LC from each of the two antibodies, possibly with slight alterations to facilitate homologous pairing of HC and LC and formation of heterodimeric HC / HC pairs.

[0202] In some embodiments, the antibody mixture comprising an anti-CCR8 antibody and a second antibody can be prepared in a single host cell line into which DNA encoding the two antibodies is introduced, using strategies described in detail in international application WO 2017 / 205014 and related U.S. application publication US 2019 / 024889. WO 2017 / 205014 and US2019 / 0248899 describe, in particular, how to prepare a mixture of two and no more than three different antibodies in a single cell line into which DNA encoding two different IgG antibodies is introduced. This description runs throughout the application, and more specifically appears on pages 50-59, Examples 1-7, and Figures 1-23 of WO2017 / 205014, the contents of which are incorporated herein by reference in their entirety for all purposes. In addition, this description appears in Examples 1-7 (paragraphs

[0518] to

[0602] ) and Figures 1-23 of US2019 / 0248899, the contents of which are incorporated herein by reference. Compared with production in two separate cell lines, the efficiency and cost-effectiveness of producing antibody mixtures in a single host cell line are much higher because it only requires the development and operation of one commercial process instead of two. In short, these methods include introducing mutations into the DNA encoding one or two antibodies, the mutations encoding partner-directed changes in the heavy chain and / or light chain of one or two antibodies to force the formation of homologous HC / LC pairs, and in some cases also prevent or inhibit the formation of non-homologous HC / LC pairs (see Figures 1-3 of WO 2017 / 205014 or US11,130,808). In some embodiments, one or more mutations encoding changes that are not conducive to heterodimers are also introduced into the DNA encoding one or two antibodies (see Figures 1 and 3 of WO 2017 / 205014 or US11,130,808).

[0203] Well-known methods can be used to generate DNA encoding HC and / or LC. Such methods include artificial synthesis of DNA sequences (e.g., by commercial suppliers such as Integrated DNA Technologies, Coralville, Iowa, USA or Genewiz, South Plainfield, NJ, USA, etc.) and ligation of DNA segments by Gibson reaction (i.e., overlapping PCR), as described in, for example, Gibson The PCR products were prepared as described in the Master Mix Operating Instructions, New England Biolabs Inc. (NEB), Version 3.3, NEB Catalog # E2611S / L, NEB Inc., Ipswich, MA, USA.

[0204] In some embodiments, the anti-CCR8 antibody and / or the second antibody in the antibody mixture containing the anti-CCR8 antibody and / or the bispecific antibody containing the anti-CCR8 antibody can contain one or more changes that increase or decrease the clearance of the antibody in vivo. Changes that increase clearance can include, for example, one or more of the following: M252A, M252L, M252S, M252R, R255K and H435R. Changes that reduce clearance include, for example, triple mutants M252Y / S254T / T256E (YTE) and double mutants T250Q / M428L (QL), etc. See, for example, Monnet et al., (2014), Combined glycol-and protein-Fc engineering simultaneously enhances cytotoxicity and half-life of a therapeutic antibody, mAbs 6(2):422-236. Other changes that have this effect can also be used. If a particular alteration within the IgG constant domain of an antibody has the effect of reducing or increasing the in vivo clearance (as defined above) of, for example, a particular human, humanized or primate IgG antibody, it is defined herein as an alteration that reduces or increases the in vitro clearance of any human, humanized or primate IgG antibody comprising such altered constant domain.

[0205] In other embodiments, the IgG anti-CCR8 antibodies described herein may include one or more changes that reduce one or more aspects of the effector function of the antibody. Examples of such changes include the following: (1) D265A or D265X in the HC of an IgG antibody (wherein X is any amino acid other than D); (2) E318X, K320X and / or K322X in an IgG2 antibody (wherein X is any amino acid other than the original amino acid); (3) D270X, K322X, P329X and / or P331X in an IgG1 antibody (wherein X is any amino acid other than the original amino acid); (4) P329A; (5) L234A, L235A and / or P329A in an IgG1 antibody; and / or (6) L234A, L235E and G237A in the IgG1 constant region.

[0206] Methods for preparing antibodies and antibody mixtures

[0207] Generally, the individual anti-CCR8 monoclonal antibodies of the invention described herein can be produced by introducing DNA encoding the antibody into a host cell, culturing the host cell under conditions suitable for producing the antibody by the cell, and recovering the antibody from the cell mass or cell supernatant. The DNA can be introduced by, for example, transfection, transformation, electroporation, gene gun microprojectile bombardment, microinjection, liposome transfection, etc. Thereafter, the antibody can be purified to eliminate components other than the desired antibody, such as host cell proteins, culture medium components, and / or unwanted antibody species, such as IgG antibody species that do not contain two heavy chains and two light chains. Such purification steps may include, for example, selective precipitation, column chromatography (e.g., using a protein A column), dialysis, etc.

[0208] Antibodies produced individually by the methods just described above can be mixed to produce a mixture. Alternatively, an antibody mixture can be produced in a similar manner, the difference being the manner in which the DNA encoding the two different antibodies is introduced into the host cell simultaneously or sequentially. Due to the promiscuous HC / HC and HC / LC pairings, a host cell containing DNA encoding two different IgG antibodies (i.e., two different heavy chains and light chains) can potentially produce up to ten different IgG antibody species. See, for example, WO 2017 / 205014. Figure 4 . In order to limit the number of such species, the antibodies may contain HC and LC partner-directed changes and / or changes that are not conducive to heterodimerization. Such changes can limit the number of major antibody species produced by the host cell. Such mixtures can be purified as described above. Similar problems may arise when bispecific IgG antibodies are produced in a single cell line. In this case, partner-directed changes can be used to ensure that only homologous HC / LC pairing occurs, and changes that favor heterodimeric HC / HC pairing can also be used. Such changes are described, for example, in U.S. Patent 8,592,562. Examples 1 and 2 of U.S. Patent 8,592,562 and the drawings referenced therein are incorporated herein by reference.

[0209] Those skilled in the art will recognize that, relative to developing and operating two commercial production processes, producing antibody mixtures in a single host cell line rather than two host cell lines represents a significant improvement in ease and efficiency of production. Developing a commercial production process for any antibody requires optimization of numerous factors, including, for example, the expression system, the host cell line (if a cell line is used for expression), the cell culture process (including physical variables, such as the use of stirred tanks, perfusion and many other culture methods, and the culture medium and feeding strategies for growing the host cell line), and antibody purification and formulation. In addition, once the process development is complete, it must be characterized and validated and transferred to a manufacturing plant for current good manufacturing practice (cGMP) production. See, for example, Li et al., (2010), Cell culture processes for monoclonal antibody production, mAbs 2(5):466-477. Therefore, it is clear that producing antibody mixtures in a single process represents a significant improvement in ease and efficiency of production, not to mention a significant reduction in cost, compared to producing in two processes.

[0210] In embodiments where the mixture comprises an anti-CCR8 antibody and a targeted inhibitor, the antibody can be prepared as described above, and the targeted inhibitor can be prepared by methods known in the art, such as chemical synthesis.

[0211] Polynucleotides and vectors

[0212] Provided are polynucleotides, such as DNA or other nucleic acids, encoding the antibodies and antibody mixtures described herein. Using the guidance provided herein, one skilled in the art can combine known or new nucleic acid sequences encoding antibodies and modify them by known methods to generate polynucleotides encoding the antibodies and antibody mixtures described herein, the antibodies comprising the V H and V L Amino acid sequence. H and V L The sequences are disclosed, for example, in the attached sequence listing and throughout this specification. In some embodiments, the polynucleotides may encode HC and / or LC comprising changes (e.g., changes directed by a partner, changes affecting effector function, and / or post-translational modifications) relative to the amino acid sequences disclosed herein. Such changes may be amino acid substitutions. In addition, such polynucleotides may encode HC and / or LC comprising one or more partner-directed changes within and / or outside the variable domain and / or one or more changes that are favorable or unfavorable to heterodimerization. Many polynucleotides encoding human, mammalian and primate immunoglobulin constant domains, such as C L , CH 1. Hinge, C H 2 and C H 3. See, e.g., Kabat et al., supra. As explained above, such constant domains can be altered to enhance or inhibit one or more of the various functions of these constant domains, such as (1) reducing or increasing in vivo clearance, (2) enhancing or inhibiting various effector functions, (3) increasing or reducing the formation of HC / HC heterodimers, and / or (4) enhancing or inhibiting the formation of homologous HC / LC pairs. Optionally, the polynucleotide sequences encoding the variable domains described herein can be combined with polynucleotide sequences encoding such constant domains to produce antibodies in any of the various forms, such as IgG (including IgG1, IgG2, IgG3 and IgG4), IgM, IgD, IgE, IgA, bispecific formats, scFv, scFv-Fc, Fab, (scFc-linker-scFv), Fab-scFv, IgG-scFv. In some embodiments, these antibodies may include changes in partner guidance and / or changes that are favorable or unfavorable for heterodimerization. In some embodiments, these antibodies may be mammalian antibodies, optionally chimeric, human, humanized or primate antibodies.

[0213] Methods for modifying polynucleotides are well known in the art, and any of these known methods can be used to prepare the polynucleotides described herein. Perhaps the most direct method for producing modified polynucleotides is to synthesize polynucleotides having the desired sequence. Many companies such as Atum (Menlo Park, Calif., USA), BlueHeron (Bothell, Washington), Genewiz (South Plainfield, New Jersey), Gen9 (Cambridge, Massachusetts) and Integrated DNA Technologies (Coralville, Iowa) provide this service. Other known methods for introducing mutations can also be used, such as site-directed mutagenesis using polymerase chain reaction (PCR). See, e.g., Zoller, (1991), New molecular biology methods for protein engineering, Curr. Opin. Biotechnol. 2(4):526-531; Reikofski and Tao, (1992), Polymerase chain reaction (PCR) techniques for site-directed mutagenesis, Biotechnol. Adv. 10(4):535-547.

[0214] The vector containing the polynucleotide (optionally DNA or mRNA) encoding the antibodies described herein and mixtures thereof can be any vector suitable for expressing the antibodies in a selected host cell. The vector can include a selective marker for selecting a host cell containing the vector and / or for maintaining and / or amplifying the vector in the host cell. Such markers include, for example, (1) genes that confer resistance to antibiotics or other toxins (e.g., ampicillin, tetracycline, or kanamycin) on prokaryotic host cells, (2) genes that supplement the nutritional deficiencies of cells, or (3) genes that operate to provide key nutrients that are unavailable from a composite or component-defined culture medium. Specific selective markers include, for example, kanamycin resistance genes, ampicillin resistance genes, and tetracycline resistance genes. Bleomycin resistance or neomycin resistance genes can also be used for selection in prokaryotic and eukaryotic host cells. As known in the art, dihydrofolate reductase (DHFR) genes and / or promoter-free thymidine kinase genes can be used for mammalian cells. See, e.g., Kingston et al., 2002, Amplification using CHO cell expression vectors, Current Protocols in Molecular Biology, Chapter 16, Units 16-23, Wiley 2002.

[0215] In addition, the vector may include one or more other sequence elements required to maintain the vector described herein and / or express the inserted sequence encoding the antibody or antibody mixture described herein. Such elements include, for example, a replication origin, a promoter, one or more enhancers, a transcription terminator, a ribosome binding site, a polyadenylation site, a multiple cloning site for the insertion of an exogenous sequence (e.g., a DNA encoding an antibody or antibody mixture described herein), and a spacer sequence between two inserted sequences such as the DNA encoding HC and LC. These sequence elements can be selected to play a role in the desired host cell to promote replication and / or amplification of the vector and the expression of the heterologous sequence inserted into the vector. Such sequence elements are well known in the art and can be obtained in a large number of commercially available vectors.

[0216] In some embodiments, polynucleotides encoding anti-CCR8 antibodies, bispecific antibodies, or antibody mixtures described herein may be carried on one or more viral vectors, optionally on an oncolytic viral vector. Examples of such viral vectors include adenovirus, adeno-associated virus (AAV), retrovirus, vaccinia virus, modified vaccinia virus Ankara strain (MVA), herpes virus, slow virus, Newcastle disease virus, measles virus, coxsackie virus, reovirus, and poxvirus vectors. In such embodiments, these viral vectors containing polynucleotides encoding antibodies or antibody mixtures described herein can be administered to patients to treat diseases. For example, in cancer patients, such viral vectors containing polynucleotides encoding antibodies or antibody mixtures can be directly administered to the main part of the tumor or cancer cell in the patient, such as by injection, inhalation (for lung cancer), topical administration (for skin cancer) and / or administration to mucosa (nucleic acid can be absorbed by it) and other possibilities. Alternatively, as described herein, such viral vectors can be administered systemically, such as orally, topically, through the mucosa or by subcutaneous, intravenous, intra-arterial, intramuscular or peritoneal injection. Similarly, polynucleotides encoding the anti-CCR8 antibodies or antibody cocktails described herein can be encapsulated in liposomes, lipid nanoparticles, or other non-viral delivery vehicles known in the art, which can be administered to a patient suffering from a disease.

[0217] The DNA or mRNA encoding one, two or more antibodies can be introduced into the host cell using any suitable method, including, for example, transfection, transduction, liposome transfection, conversion, gene gun microprojectile bombardment, microinjection or electroporation. In some embodiments, the DNA or mRNA encoding one, two or more full-length antibodies can be introduced into the host cell. Such methods are known in the art and are described in, for example, Kaestner et al., (2015), Conceptual and technical aspects of transfection and gene delivery, Bioorg.Med.Chem.Lett.25:1171-1176, which are incorporated herein by reference.

[0218] Pharmaceutical compositions and methods of administration

[0219] The antibodies, antibody mixtures, bispecific antibodies, mixtures comprising anti-CCR8 antibodies and targeted inhibitors, polynucleotides and / or carriers described herein can be administered in pharmaceutically acceptable formulations. With regard to the antibody mixture, each antibody can be formulated and administered alone or together. With regard to mixtures containing anti-CCR8 antibodies and targeted inhibitors, antibodies and inhibitors can be formulated and administered alone or together. A large number of pharmaceutical preparations are known in the art. Many such preparations are described in REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY, 21st edition, Lippincott Williams & Wilkins, Philadelphia, PA, 2005, the relevant parts of which are incorporated herein by reference. Such pharmaceutically acceptable preparations can be, for example, liquids such as solutions or suspensions, solids such as pills, capsules, pastes or gels. Liquid preparations can contain, for example, one or more of the following components: buffers, excipients, salts, sugars, detergents and chelating agents. It may be designed to maintain the functionality of the antibody, antibody mixture, polynucleotide or vector and to be well tolerated by the patient.

[0220] Polynucleotides and proteins (such as antibodies) are usually administered parenterally rather than orally.Depending on the preparation, oral administration may expose proteins or polynucleotides to the acidic environment of the stomach, which may inactivate the proteins or polynucleotides.In some embodiments, specific preparations may allow oral specific proteins or polynucleotides, wherein the proteins or polynucleotides are insensitive to gastric acid or are fully protected from the impact of acidic environments, such as by specific coatings on pills or capsules.Preparations can also be administered by mucosal administration, including, for example, intranasal, vaginal, rectal or oral administration, or used as inhalants.In some embodiments, preparations can also be applied topically.Usually, antibodies and polynucleotides are administered by injection of liquid preparations.Injection can be, for example, subcutaneous, intravenous, intra-arterial, intralesional (such as intratumoral), intramuscular or peritoneal injection.

[0221] As described above, targeted inhibitors that are small molecules can be administered orally or by other methods including injection. Suitable formulations for oral administration may include, for example, liquids such as solutions or suspensions, pastes, gels, or solids such as pills or capsules.

[0222] Host cells containing polynucleotides encoding antibodies or antibody mixtures

[0223] The host cell containing one or more polynucleotides encoding one or more antibodies can be any of the various cells suitable for expressing recombinant proteins. They include, for example, gram-negative or gram-positive prokaryotes, such as bacteria such as Escherichia coli, Bacillus subtilis or Salmonella typhimurium. In other embodiments, the host cell can be a eukaryotic cell, including species such as Saccharomyces cerevisiae, Schizosaccharomyces pombe, or eukaryotic organisms of Kluyveromyces, Candida, Noctua, or any cell capable of expressing heterologous polypeptides. In other embodiments, the host cell can be a mammalian cell. Many mammalian cell lines suitable for expressing heterologous polypeptides are known in the art and can be obtained from various suppliers, including, for example, American Type Culture Collection (ATCC).Suitable mammalian host cell lines include, for example, COS-7 line (ATCC CRL 1651) (Gluzman et al., (1981), SV40-transformed simian cells support the replication of early SV40 mutants, Cell 23(1):175-182), L cells, C127 cells, 3T3 cells (ATCC CCL 163), Chinese hamster ovary (CHO) cells or their derivatives such as Veggie CHO and related cell lines grown in serum-free medium (Rasmussen et al., (1998), Isolation, characterization and recombinant protein expression in Veggie-CHO: a serum-free CHO host cell line, Cytotechnology 28:31), CHO K1 and CHO pro-3 cell lines and their derivatives such as DUKX-X11 and DG44 cell lines deficient in dihydrofolate reductase (DHFR) activity, HeLa cells, baby hamster kidney (BHK) cells (e.g. ATCC CRL 10), CVI / EBNA cell line derived from African green monkey kidney cell line CVI (ATCC CCL70) (as described in McMahan et al. (1991), A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types, EMBO J. 10 (10): 2821-2832), human embryonic kidney (HEK) cells such as HEK 293, 293EBNA or MSR 293, human epidermal A431 cells, human Colo205 cells, HL-60 cells, U937 cells, HaK cells, Jurkat cells, HepG2 / 3B cells, KB cells, NIH 3T3 cells, S49 cells, PER.C6 (Crucell), CAP and CAP-T cells (CEVEC) and mouse myeloma cells, including NS0 and Sp2 / 0 cells. Other prokaryotic, eukaryotic or mammalian cell types capable of expressing heterologous polypeptides can also be used.

[0224] Treatment

[0225] Treg provides immune self-tolerance and limits the activity of cytotoxic lymphocytes. An increase in intratumoral Tregs has been observed in many types of cancer and is thought to prevent effective antitumor immune responses. Depletion of Tregs in several preclinical animal models showed increased antitumor responses (Van Damme et al., J Immunother Cancer. 2021Feb; 9(2): e001749.doi: 10.1136 / jitc-2020-001749). However, due to the lack of cell targets specific to intratumoral Tregs rather than peripheral Tregs, therapeutic depletion of tumor-associated Tregs in human patients has become difficult.

[0226] CCR8 is a therapeutic target that can be used to deplete intratumoral Tregs and enhance antitumor immune responses because CCR8 expression is increased on tumor-associated Tregs but not on peripheral Tregs. Cancer types with relatively high levels of intratumoral Tregs expressing CCR8 provide the best reason to treat with anti-CCR8 therapeutic antibodies. Breast cancer is one such indication. Colorectal cancer represents another indication because multiple studies have shown an increased ratio of Tregs to CTLs in colorectal cancer. In addition, increased CCR8 expression on intratumoral Tregs in colorectal cancer lesions is associated with poor prognosis (deLeeuw et al., Clin Cancer Res. 2012 Jun 1; 18(11): 3022-9. doi: 10.1158 / 1078-0432.CCR-11-3216). Analysis of CTLs in colorectal cancer confirmed increased PD-1 expression, indicating that CTLs have been exhausted. Consistent with the proposed immunosuppressive role of CCR8-expressing Tregs, PD-1-expressing CTLs from colorectal adenocarcinoma tumors had an impaired immune response to TCR stimulation.

[0227] Antitumor immunity is a balance between antitumor factors such as effector T cell activity and immunosuppressive factors such as Treg. Reducing the inhibitory effect of intratumoral Treg has been considered an effective antitumor treatment. Preclinical animal studies have shown that depletion of intratumoral Treg can enhance antitumor immune responses. Antitumor activity is enhanced by combination with checkpoint inhibitors such as anti-PD-1 antibodies (Campbell et al., Cancer Res. 2021 Jun 1; 81 (11): 2983-2994. doi: 10.1158 / 0008-5472. CAN-20-3585).

[0228] According to the present invention, preclinical studies conducted by the inventors have confirmed that anti-CCR8 antibodies with enhanced antibody-dependent cellular cytotoxicity can significantly deplete Treg from tumors. This is expected to reduce the immunosuppressive effect of intratumoral Treg. It is contemplated herein to co-administer with additional therapeutic agents such as anti-PD-1 / CTLA-4 antibodies to enhance effector T cell function to improve anti-tumor effects. CCR8 expression increases on Treg cells located in tumors rather than on peripheral Treg or Treg near tumors. Therefore, the inventors' preclinical data show that this differential expression of CCR8 will provide a wider dosing window, allowing depletion of tumor-associated Treg while retaining Treg with low CCR8 expression in the periphery. In addition, a combination of anti-CCR8 antibodies and PSB205MabPair is contemplated herein to achieve high clinical efficacy for the treatment of a variety of solid tumors. In this combination, three different antibodies can work together to maximize the potential of immune checkpoint inhibitors.

[0229] In view of the data in the following examples and the available published information, the anti-CCR8 antibodies described herein, bispecific antibodies comprising anti-CCR8 antibodies and another antibody, and / or mixtures comprising anti-CCR8 antibodies and another antibody or targeted inhibitors, and / or polynucleotides and / or vectors encoding the one or more antibodies can be used to treat various cancers. These methods can be used to treat a variety of cancers. Specific cancers in this group include cancers associated with Treg upregulation, infiltration and / or activity. Examples of such Treg-related cancers include breast cancer, colon cancer, melanoma, leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, lymphoma, lung cancer, esophageal cancer, hepatocellular carcinoma, pancreatic adenocarcinoma, pancreatic ductal adenocarcinoma, gastric cancer, ovarian cancer, head and neck cancer, glioma, glioblastoma, squamous cell carcinoma, renal cell carcinoma, prostate cancer and bladder cancer. Specific cancers in this group include cancers associated with viruses. Examples of such virus-associated cancers include Hodgkin lymphoma, non-Hodgkin lymphoma, Kaposi's sarcoma, astrocytoma, glioblastoma, T-cell leukemia and lymphoma, acute myeloid leukemia, Merkel cell carcinoma, head and neck cancer, acute myeloid leukemia, and cancers of the bone, throat, mouth, liver, cervix, stomach, prostate, vagina, vulva, and lung. In embodiments where a mixture comprising an anti-CCR8 antibody and another antibody that binds to a cancer antigen is administered, the other antibody (which may be an IgG antibody) may comprise an alteration that enhances antibody-dependent cellular cytotoxicity (ADCC).

[0230] Combinations of anti-CCR8 antibodies described herein and antibodies that bind to related immunomodulatory proteins, such as CTLA4, PD1, PDL2, MIC-A, MIC-B, LILRB1, and LILRB2, can also be used to treat cancer. Alternatively, polynucleotides or vectors encoding any of these mixtures can be used to treat cancer.

[0231] In other embodiments, an antibody mixture comprising an anti-CCR8 antibody described herein and a second antibody to a second antigen, a bispecific antibody comprising an anti-CCR8 antibody and a second antibody to a second antigen, or a polynucleotide and / or a vector encoding such a mixture or bispecific antibody, can be used to treat cancers in which the second antigen is highly expressed on the surface of cancer cells. The second antibody may comprise a change that enhances the ability of the second antibody to elicit an ADCC response. For example, a combination of an anti-CCR8 antibody and an anti-HER2 antibody, a bispecific anti-CCR8-anti-HER2 antibody, or a polynucleotide and / or a vector encoding one or more such antibodies can be used to treat cancers in which cancer cells express HER2, such as breast cancer, bladder cancer, cervical cancer, colorectal cancer, esophageal cancer, gallbladder cancer, or non-small cell lung cancer or bile duct cancer (extrahepatic and intrahepatic), gastric adenocarcinoma, head and neck cancer, hepatocellular carcinoma, or small intestinal malignancies. Similarly, a combination of an anti-CCR8 antibody and an anti-EGFR antibody, a bispecific anti-CCR8-anti-EGFR antibody, or a polynucleotide and / or vector encoding the same can be used to treat cancers in which cancer cells express EGFR, such as head and neck cancer, ovarian cancer, cervical cancer, bladder cancer, esophageal cancer, gastric cancer, breast cancer, endometrial cancer, colon cancer, colorectal cancer, biliary tract (e.g., gallbladder) cancer, non-small cell lung cancer, gastric cancer, prostate cancer, kidney cancer, pancreatic cancer, or ovarian cancer. In some embodiments, a combination of an anti-CCR8 antibody and an anti-carcinoembryonic antigen-related cell adhesion molecule 5 (CEA) antibody can be used to treat colon cancer, or an anti-CRR8 antibody and an anti-prostate-specific antigen (PSA) antibody can be used to treat prostate cancer. Similarly, a combination of an anti-CCR8 antibody and an anti-claudin 18.2 (CLDN18.2), anti-B7 homolog 4 (B7H4) or anti-B7 homolog 3 (B7H3; CD276) antibody, a bispecific anti-CCR8 and anti-CLDN18.2, anti-B7H4 or anti-B7H3 antibody can be used to treat cancers in which cancer cells overexpress CLDN18.2, B7H4 or B7H3, respectively. Alternatively, these antibodies or polynucleotides and / or vectors encoding them can be administered alone or as a mixture. For example, an anti-CCR8 antibody can be administered before a second antibody, or vice versa. Or two antibodies or polynucleotides or vectors can be administered simultaneously but separately.

[0232] In other embodiments, if a polynucleotide or vector is used for the treatment described herein, the vector can be, for example, an oncolytic viral vector or an expression vector and can be administered to a patient to enhance the immune response and / or treat various conditions, including, for example, the various cancers and various infections discussed above in conjunction with the anti-CCR8 antibodies, mixtures containing such antibodies, and the bispecific antibodies described herein.

[0233] The anti-CCR8 antibody, an antibody mixture comprising an anti-CCR8 and a second antibody administered alone or as a mixture, an anti-CCR8 antibody (or a polynucleotide encoding the antibody) and a targeted inhibitor or a mixture of a STING agonist can be administered alone or as a mixture, and a bispecific antibody comprising an anti-CCR8 antibody and a second antibody or a polynucleotide or vector encoding such an antibody or combination can be administered together with an additional therapy, which is administered before, after and / or simultaneously with the antibody, combination or polynucleotide or vector. The additional therapy can be selected from the group consisting of immunomodulatory molecules, radiation, chemotherapeutic agents, targeted biologics, targeted inhibitors and / or oncolytic viruses. In some embodiments, the additional therapy can be an agonist of the STING pathway, such as cGAMP or DNA.

[0234] In some embodiments, the additional therapy can be (1) a macromolecule or small molecule antagonist of PDL1, PDL2 or PD1, (2) an agonist of the STING pathway, such as cGAMP, DNA and / or a STING agonist listed in Table 10, (3) a targeting molecule, such as HER2, EGFR, TIGIT, CCR4, CSFR1a, B7H3, B7H4, CD96 or CD73, (4) an agonist of GITR, 4-1BB, OX40, CD27 or CD40, (5) an oncolytic virus, such as talimogene laherparepvec (IMLYGIC TM ), (6) bispecific T cell engagers (BiTEs), such as blinatumomab, (7) targeted inhibitors, such as indoleamine 2,3 dioxygenase (IDO) inhibitors, (8) tyrosine kinase inhibitors, (9) anti-angiogenic agents, such as bevacizumab, or (10) antibody-drug conjugates.

[0235] If the additional therapy is a chemotherapeutic agent, it can be, for example, busulfan, temozolomide, cyclophosphamide, lomustine (CCNU), streptozotocin, methyl lomustine, cis-diamine dichloroplatinum, thiotepa, aziridinyl benzoquinone, cisplatin, carboplatin, melphalan hydrochloride, chlorambucil, ifosfamide, mechlorethamine hydrochloride, carmustine (BCNU), doxorubicin (doxorubicin), daunorubicin, mithramycin, daunomycin, idarubicin, mitomycin C, bleomycin, vincristine, vindesine, vinblastine, vinorelbine, paclitaxel , docetaxel, VP-16, VM-26, methotrexate with or without leucovorin, 5-fluorouracil with or without leucovorin, 5-fluorodeoxyuridine, 5-fluorouracil, 6-mercaptopurine, 6-thioguanine, gemcitabine, cytarabine, 5-azacytidine, hydroxyurea, deoxycoformycin, fludarabine, etoposide, irinotecan, topotecan, actinomycin D, dacarbazine (DTIC), mAMSA, procarbazine, hexamethylmelamine, pentamethylmelamine, L-asparaginase and / or mitoxantrone. See, e.g., Cancer: Principles and Practice of Oncology, 4th edition, DeVita et al., eds., JB Lippincott Co., Philadelphia, Pa. (1993), the relevant portions of which are incorporated herein by reference.

[0236] If the additional therapy is radiation, the radiation therapy may include external beam radiation and / or internal radiation using, for example, photon, proton, or electron beams. There are many types of external radiation, including, for example, three-dimensional conformational radiation therapy, intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT), Stereotactic radiotherapy and stereotactic body radiotherapy. Internal radiation methods include, for example, brachytherapy or systemic administration of radioactive substances (e.g., radioiodine). Recent publications have shown that the combined use of radiotherapy with immunomodulatory therapeutic agents such as antagonists of CTLA4 or PD1 can effectively treat certain cancers. See, for example, Sprie et al., (2016), Synergy of radiotherapy and PD-1blockade in Kras-mutant lung cancer, JCI Insight 1(9): e87415 (doi: 10.1172 / jci.insight.87415); Formenti et al., (2018), Radiotherapy induced responses of lung cancer to CTLA-4blockade, Nature Medicine 24(12): 1845-1851. Therefore, the addition of radiation therapy to some of the immunomodulatory therapies described herein, such as anti-CCR8 antibodies and mixtures containing them, may provide additional benefits.

[0237] About antibody or its mixture, they can be applied to the patient with therapeutically effective dose at appropriate intervals.Therapeutically effective dose can be determined by methods known in the art, including testing in in vitro assays, rodent and / or primate model systems and / or clinical trials.In some embodiments, the single dose of antibody or antibody mixture can be about 0.01 milligram / kilogram body weight (mg / kg) to about 50mg / kg, about 0.05mg / kg to about 10mg / kg, about 0.1mg / kg to about 10mg / kg or about 0.5mg / kg to about 7mg / kg. "Single dose" referred to herein can be part of an ongoing treatment regimen, which includes multiple continuous single doses in a time period of several days, weeks, months or years.A single dose can be a dosage of about 0.05mg / kg, 0.1mg / kg, 0.5mg / kg, 1mg / kg, 2mg / kg, 3mg / kg, 4mg / kg, 5mg / kg, 6mg / kg, 7mg / kg, 8mg / kg, 9mg / kg or 10mg / kg. Similarly, the antibody or antibody mixture may be dosed at about 0.37 mg / m2 skin surface area (mg / m 2 ) to about 1850 mg / m 2 , about 0.5mg / m 2 About 370 mg / m 2 , about 3.7mg / m 2About 370 mg / m 2 or about 18.5 mg / m 2 To about 259mg / m 2 A single dose may be about 10 mg / m 2 , 20mg / m 2 , 37mg / m 2 , 74mg / m 2 , 111mg / m 2 , 148mg / m 2 , 185mg / m 2 , 222mg / m 2 , 259mg / m 2 , 296mg / m 2 , 333mg / m 2 or 370 mg / m 2 Similarly, the dosage of the antibody or antibody mixture can be administered at a dosage of about 0.62 mg to about 3100 mg, about 1 mg to about 620 mg, about 6.2 mg to about 620 mg, or about 10 mg to about 434 mg. A single dose can be about 0.5, 1, 3, 6, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, or 100 mg.

[0238] A single dose of (1) an antibody, (2) an antibody mixture, (3) a combination of antibodies administered alone, (4) a targeted inhibitor administered before, after, concurrently, or simultaneously with an anti-CCR8 antibody or a polynucleotide encoding an anti-CCR8 antibody, or (5) a polynucleotide encoding an anti-CCR8 antibody or an antibody mixture containing an anti-CCR8 antibody, can be administered once or twice over a period of time or at intervals. For example, the agent can be administered daily, every other day, twice a week, once a week, once every ten days, once every two weeks, once every three weeks, once a month, or once every two months, three months, four months, five months, six months, seven months, eight months, nine months, ten months, eleven months, or twelve months. Administration can last, for example, about one to four weeks, about one to six months, about six months to one year, about one to two years, or up to five years. In some cases, administration can be interrupted and restarted. In some embodiments, a mixture comprising anti-CCR8 and another antibody can be administered so that the two antibodies can be administered simultaneously. After one or more doses of the mixture, the anti-CCR8 antibody or another antibody can be administered alone. In some embodiments, administration of the antibody or antibody cocktail may be interrupted and resumed one or more times.

[0239] In the case of one or more polynucleotides or vectors encoding an antibody or antibody cocktail described herein, the dosage may be, for example, about 5 x 10 9The number of copies of polynucleotide or vector per kilogram of body weight (copies / kg) is about 10 15 Copies / kg, about 10 10 Copies / kg to about 10 14 copies / kg or about 5×10 10 Copies / kg to about 5×10 13 copies / kg. Alternatively, the dose may be about 10 10 , 10 11 , 10 12 , 10 13 , 5×10 13 , 10 14 , 2×10 14 , 3×10 14 , 4×10 14 , 5×10 14 , 6×10 14 ,7×10 14 , 8×10 14 ,9×10 14 or 10 15 The frequency of administration can be adjusted as needed and can be as described above or, for example, daily, every other day, twice a week, once a week, once every ten days, once every two weeks, once every three weeks, once a month, or once every two months, three months, four months, five months, six months, seven months, eight months, nine months, ten months, eleven months, or twelve months.

[0240] In the case where a targeted inhibitor or STING agonist (e.g., cGAMP) is administered before, after, or simultaneously with an anti-CCR8 antibody, the therapeutically effective dose can be determined by methods known in the art, including testing in in vitro assays, rodent and / or primate model systems, and / or clinical trials. Exemplary dose ranges for such inhibitors can be 0.001 mg / kg to 2000 mg / kg, 0.01 mg / kg to 100 mg / kg, 0.1 mg / kg to 100 mg / kg, 1 mg / kg to 50 mg / kg, among other possibilities. In the case of a STING agonist, it can be administered topically, for example by injection into a tumor or localized area of ​​infection. Other methods of administration are also possible.

[0241] Having generally described the present invention above, the following specific examples are provided to illustrate the present invention, but not to limit its scope. It should be understood that various changes and modifications may be made to the present invention, which are consistent with the spirit of the present invention described herein and will be apparent to those skilled in the art. These changes and modifications are within the scope of the present invention described herein (including the appended claims).

[0242] Example

[0243] Example 1: Binding affinity of anti-CCR8 monoclonal antibodies

[0244] The affinity of candidate antibodies for human CCR8 was assessed using SPR on a Biacore 3000 instrument. Anti-CCR8 Fab fragments were flowed over the cells in the chip, and multiple blank (running buffer) injection runs were also performed to subtract system artifacts. TM Software (BioLogic Software, Pty, Australia) aligns, double-deducts (doublereference) and fits the data. Biacore analysis confirms that the affinity of lead candidate Fab 51 to the recombinant hCCR8 N-terminal fused to the N-terminal of the Fc region of human IgG1 is 647pM (Fig. 1). By iteratively modifying the amino acid residues in both CDR and framework regions to improve binding affinity and specificity, the binding affinity to human CCR8 is improved (from 1.62nM to 647pM, an increase of 2.5 times) compared with the original anti-CCR8 antibody candidate. The combination of anti-CCR8 antibodies and CCR8 is then examined in HEK293 cells or P815 cells transfected with full-length hCCR8. Lead anti-CCR8 antibody candidate 1187 shows high affinity binding to transfected cells, while anti-DNP control antibody shows the lowest level of binding ( Figure 2B The binding specificity of 1187 was assessed by staining HEK293 cells expressing an unrelated GFP protein at a concentration (100 ug / ml) close to the Cmax concentration of the therapeutic dose (10 mg / kg). Unlike the benchmark anti-CCR8 antibody 23411 (Bayer), 1187 showed little binding to HEK293 cells expressing an unrelated GFP protein ( Figure 2D ).

[0245] Example 2: Selective binding of anti-CCR8 antibodies to CD4+Foxp3+Treg

[0246] Activation of tumor-resident CD4+T cells can lead to the development of an immunosuppressive Foxp3+Treg phenotype. This pathway is independent of Treg migration to the tumor. Elimination of intratumoral CD4+Foxp3+Tregs is the mechanism of action of the lead candidate 1187 therapeutic antibody. In contrast, binding and eliminating CD4+, Foxp3-T cells is not ideal. Engineered candidate anti-CCR8 antibodies were tested for specific binding to CD4+Foxp3+T cells expressing CCR8 and nonspecific binding to CCR8-CD4+, Foxp3-T cells. In brief, human PBMCs were stimulated with OKT3 (anti-CD3) to generate a mixed population of CD4+Foxp3+T cells and CD4+Foxp3-T cells. The cells were immunostained with fluorescently labeled antibodies against huCD4 or huCCR8, fixed, permeabilized, and immunostained for intracellular Foxp3. Consistent with the proposed mechanism of action, the parent antibody (455) and several engineered candidate anti-CCR8 antibodies (953, 1047, and 1187) showed specific binding to 50-60% of CD4+Foxp3+ T cells ( Figure 3A -C). More importantly, at a therapeutic concentration of 100 μg / ml, antibodies 1187 and 1047 showed no binding to CD4+Foxp3- T cells ( Figure 3D ), which is in contrast to the parental 455, 953 and the benchmark anti-CCR8 antibody 10A11 (Shionogi Inc.). This indicates selective binding to CD4+Foxp3+Tregs without adverse binding to CD4+Foxp3- T cells, which in turn suggests that 1187 and 1047 will have improved on-target effects, fewer side effects, and better safety profiles than other anti-CCR8 antibodies than the parent antibodies. The binding specificity of the lead candidate 1187 was also tested in resting PBMCs and PBMCs stimulated with IL-2 (200U / ml) for 2 days. Antibody 1187 (20ug / ml) showed specific binding to 15% of CD4+Foxp3+ cells expressing high levels of Foxp3, while its binding to CD4+Foxp3- and CD4+Foxp3 intermediate cells was similar to that of the isotype control anti-RSV antibody ( Figure 3G ). Stimulation with IL-2 did not alter the pattern of 1187 staining on PBMC-derived T cells ( Figure 3H Since higher expression of Foxp3 is associated with the most suppressive Treg population, depletion of CD8+ Tregs with 1187 would eliminate the highly suppressive Tregs found within the tumor while preserving other Tregs to avoid overt autoimmunity.

[0247] Example 3: Anti-CCR8 Antibodies Lack Polyreactivity

[0248] Multiple studies have demonstrated that there is an association between increased polyreactivity or nonspecific binding of antibodies and shortened circulation half-life or increased clearance (Dyson et al., MAbs. Jan-Dec 2020; 12(1): 1829335. doi: 10.1080 / 19420862.2020.1829335). The polyreactivity of candidate antibodies against activated CD4+ and CD8+ T cells and dead or dying Jurkat cells was assessed. As evaluated in multiple assays, the original chimeric mouse / human anti-CCR8 antibody and some iteratively improved candidate antibodies were observed to show a certain polyreactivity. Candidate 1187 was selected as a lead for further development. The binding specificity of 1187 is confirmed by its lack of nonspecific binding to CD4+Foxp3-T cells at therapeutic concentrations (100 μg / ml) in Figures 2 and 3, as well as normal clearance and half-life in hFcRn Tg32 transgenic mice (Figure 17).

[0249] Since it is known that polyreactive antibodies bind apoptotic cells, the polyreactive binding of anti-CCR8 antibodies is further evaluated using dying Jurkat T cells. Doxorubicin (17uM) is added to Jurkat T cells to induce apoptosis overnight. The apoptotic cells are then incubated with anti-CCR8 antibodies at a concentration of 100ug / ml. After washing with PBS, the antibodies bound to apoptotic cells are detected by polyclonal goat anti-human Fc antibodies coupled to APC. In this assay, anti-RSV and anti-DNP antibodies are used as negative controls. Compared with the anti-CCR8 benchmark, candidate 1187 shows a low polyreactivity comparable to anti-RSV and anti-DNP, while most benchmark antibodies show significantly higher binding to apoptotic cells ( Figure 4 ).

[0250] Example 4: Anti-CCR8 Binding Epitope

[0251] CCL1 binds to both the N-terminus and the second extracellular domain of CCR8. To block the CCL1-CCR8 interaction, the antibody needs to bind to both separate domains simultaneously. The differences in binding epitopes between 1187 and the benchmarks were determined using a competition assay. Biotinylated 1187 was mixed with unlabeled 1187 or other benchmarks in a 1:1 molar ratio. The mixture was then used to stain hCCR8-transfected 293 cells. Binding of biotinylated 1187 was detected by APC-conjugated streptavidin. As expected, unlabeled 1187 blocked the binding of biotinylated 1187, while the irrelevant antibody rituximab had no effect. Among the known benchmarks, 4A19 was the only antibody that blocked the binding of biotinylated 1187, indicating that 4A19 (BMS) and 1187 have the same binding epitope, while the other benchmarks bind to different epitopes ( Figure 5 ).

[0252] Example 5: Blockade of CCL1-CCR8 interaction

[0253] The human CCR8 protein is located in the plasma membrane and consists of an extracellular N-terminal region, seven transmembrane regions, and an intracellular C-terminal region. Crystal structure and mechanism studies have shown that the extracellular N-terminal region combines with extracellular loop 2 to interact with CCL1 and other chemokine ligands. One of the proposed mechanisms of the therapeutic anti-CCR8 antibodies of the present invention is to block the binding of CCL1 to the extracellular N-terminal region of the CCR8 protein, thereby preventing receptor activation and chemotactic migration (Treg movement to the tumor site).

[0254] The ability of the parent antibody 455 and the engineered variant 953 to block the interaction of CCL1 with CCR8 was first evaluated using CHO cells transfected with hCCR8 and a beta-arrestin reporter gene (Discover X). Recombinant CCL1 induced a bell-shaped response curve typical of chemokines. Addition of increasing concentrations of anti-CCR8 antibody in the presence of 30 nM CCL1 blocked the CCL1-induced signal in a dose-dependent manner. Addition of 953 alone without CCL1 did not induce any signal. Since internalization of chemokine receptors (including CCR8) generally requires a beta-arrestin signal, the lack of a beta-arrestin response to 953 indicates that binding of 953 and its derivatives to the CCR8 epitope does not lead to CCR8 internalization ( Fig. 6A ).

[0255] The ability of anti-CCR8 antibodies to block the interaction between CCL1 and CCR8 in CCL1-mediated chemotaxis was further evaluated. P815 cells stably transfected with human full-length CCR8 protein were placed on an 8uM filter in a chemotaxis chamber (Neuroprobe). 1nM recombinant CCL1 was added to the bottom well of the chamber. Various concentrations of Fab fragments from anti-CCR8 antibodies were added to the top chamber. After 4 hours, chemotaxis was determined by counting P815 cells that migrated to the lower well containing human CCL1 ( Figure 6B -C). Cell counting was performed using CellTiter Glow (Promega). The Fab fragment of 1187 blocked CCL1-mediated chemotaxis with an IC 50 About 35ng / ml ( Figure 6B Furthermore, antibody 1187 was more effective than the benchmark anti-CCR8 antibody 10A11 (Shionogi) in blocking CCL1-mediated chemotaxis ( Figure 6C ).

[0256] The potency of candidate 1187 in blocking CCL1-induced chemotaxis was compared with other benchmarks. P815 cells transfected with hCCR8 were first incubated for 30 minutes with serial dilutions of 1187 or benchmarks 4A19 or B16 or K17 (all in the form of complete IgG). Anti-RSV IgG1 (100ug / ml) was added to the culture to block FcR interference on P815 cells. CCL1-induced chemotaxis was performed as described above. Candidate 1187 showed higher inhibitory activity than benchmarks 4A19, B16 and K17 ( Fig. 6E ).

[0257] Example 6: Treg depletion

[0258] Effective depletion of suppressive CD4+Foxp3+Tregs is the therapeutic mechanism of action of anti-CCR8 antibodies. Therefore, anti-CCR8 antibodies were designed to have an IgG1 isotype. After confirming that the anti-CCR8 lead candidates can bind to CD4+Foxp3+ cells in vitro, it was next determined whether these candidates could deplete these Treg cells. Human PBMCs were first stimulated with different concentrations of OKT3 (anti-CD3 1ug / ml, 100ng / ml, 10ng / ml) antibodies for 3-5 days to stimulate the activation and development of CD4+Foxp3+T cells. Anti-CCR8 antibodies were added to the cultures on day 1 to test antibody-mediated killing of regulatory T cells. On day 5, Treg depletion was quantified by immunostaining CD4+Foxp3+T cells and then counting the remaining Treg cells by flow cytometry. Lead candidate 1187 and other anti-CCR8 antibodies depleted Tregs in PBMCs stimulated with different concentrations of OKT-3 ( Figure 7B The efficacy of the anti-CCR8 antibodies was further tested in PBMCs stimulated with 100 ng / ml OKT-3. Lead candidate 1187 was more potent than the anti-CCR8 benchmark antibody clone 10A11 from Shionogi Inc ( Figure 7C Anti-CCR8 antibodies reduced the number of CD4+Foxp3+T cells by 50-60%, which is consistent with the percentage of CCR8+CD4+Foxp3+T cells observed in activated PBMCs ( Figure 3B ).

[0259] In contrast to its low expression on peripheral Tregs, CCR8 is preferentially expressed on tumor-associated Tregs from several types of cancer. This specificity and differential expression make CCR8 an attractive target for therapies targeting tumor-associated Treg depletion compared to other Treg targets that may be expressed on other cell types. It has been demonstrated that reducing fucose levels in antibodies increases binding to FcγRIIIa, resulting in enhanced ADCC activity (eADCC). To enhance its ADCC activity, the lead candidate 1187 was expressed in CHO culture containing the fucose analog 2-fluorofucose (2FF) to reduce its fucose levels (1187+2FF; which is afucosylated). The biological activity of 1187+2FF was compared to that of unmodified 1187. As expected, antibody 1187+2FF exhibited increased binding to FcγRIIIa expressed on CHO cells compared to unmodified 1187 ( Fig. 8A Meanwhile, 1187+2FF was more effective than 1187 in Treg depletion (Fig. 8, panel B), likely due to increased binding affinity to FcγRIIIA on effector cells.

[0260] Antibody 1187 was also tested for Treg depletion in IL-2 stimulated PBMC and fresh PBMC. IL-2 (200 U / ml) was added to PBMC in culture for 2-3 days to enhance NK cell activity. The addition of IL-2 did not alter the expression of CCR8 on CD4+Foxp3high cells ( Figure 3G -H). 10ug / ml of antibodies 1187, 1187+2FF, and control antibodies were added to PBMCs. After incubation overnight at 37°C, cells were stained with anti-CD4, anti-Foxp3, and anti-CD19 antibodies as described above. Elimination of CD19+ cells by rituximab demonstrated ADCC activity of the culture. Flow cytometry was used to count the number of CD4+Foxp3-, CD4+Foxp3+, and CD4+Foxp3high cells. Figure 3H The binding mode of 1187 in the 24-well plate was consistent with enhanced ADCC by reducing fucosylation, with 1187 and 1187+2FF eliminating 40% and 60% of CD4+Foxp3high cells, respectively ( Fig.8D Unlike CD4+Foxp3high cells, both 1187 and 1187+2FF had only a small effect on total CD4+Foxp3+ cells and no effect on CD4+Foxp3- cells ( Fig.8D Similar Treg cell depletion patterns were also observed in fresh PBMCs for 1187 and 1187+2FF ( Fig. 8E ).

[0261] Since CCR8 is only expressed by a small portion of CD4+Foxp3+ cells, additional surface markers are used to further evaluate the specificity of Treg depletion. Since GITR and ICOS are known markers associated with T cell activation and tumor Treg CCR8 expression, both anti-GITR and ICO antibodies are added to flow cytometry analysis. Fresh PBMCs are separated using Ficoll gradients. After incubation with the serial dilutions of PSB114 (1187+2FF) for 4-5 days, cells are stained with anti-CD4, anti-GITR, anti-ICOS and anti-Foxp3. Cells expressing Fox3 and GITR and cells expressing Foxp3 and ICOS are counted by flow cytometry. In order to reduce the collection differences between samples, the number of cells is normalized to the number of CD4T cells in each sample. At a concentration of 10ug / ml, PSB114 (i.e., 1187+2FF) depleted 10-20% of total Foxp3+ cells and 80-90% of Foxp3+GITR+ and Foxp3+ICOS+ cells. Therefore, in Foxp3+Treg cells, PSB114 specifically depletes Foxp3+GITR+ICOS high populations (Figure 9). In 9 different healthy donors, when the depletion of Foxp3+ICOS+ was used as a readout, the EC50 of PSB114-mediated Treg depletion in fresh PBMCs ranged from 0.1ng / ml to 75ng / ml, with an average value of 23ng / ml. Since the binding of PSB114 to Fc receptors may also affect monocytes, the number of large-sized monocytes was also monitored in the Treg depletion experiment. In all donors, PSB114 concentrations between 1ug / ml and 10ug / ml induced a 2-3 fold increase in large monocytes ( Fig.11A ).

[0262] FCRIIIa-mediated cytotoxicity and FCRIIa-mediated phagocytosis are two major cell-mediated killing mechanisms induced by antibody binding. These two activated Fc receptors (FCRIIIa and FCRIIa) are mainly expressed on NK cells and monocytes, respectively. In order to determine which of the two receptors is responsible for Treg depletion and monocyte expansion induced by PBS114, PBMCs were pre-incubated with anti-FCRIIIa alone (10ug / ml, clone 3G8, biolegend) or anti-FCRIIa alone (10ug / ml, clone AT10, Biorad) or a combination thereof. PSB114 (10ug / ml) was then added to the culture to deplete Treg. Pre-incubation with anti-FCRIIIa alone not only reversed 80% of Treg depletion, but also moderately reduced monocyte expansion. Anti-FcRIIa alone does not affect Treg depletion mediated by PSB114, but moderately reduces monocyte expansion. The combination of two FC receptor blockers did not further reverse Treg depletion but further reduced monocyte expansion ( Fig.10 and Fig. 11B These results suggest that PBS114-induced Treg depletion is primarily mediated by FCRIIIa, and that PSB114-induced monocyte expansion requires both FCRIIIa and FCRIIa.

[0263] Example 7: Enhancement of T cell proliferation and cytokine production

[0264] Regulatory T cells inhibit T cell activation. Therefore, depletion of CD4+Foxp3+ cells during T cell activation using anti-CCR8 antibodies is expected to enhance T cell proliferation and cytokine production. T cell proliferation and TNF-α production in PBMCs stimulated with OKT-3 were evaluated in the presence of anti-CCR8. Antibody 1187 increased both T cell proliferation and TNF-α production in PBMCs from 3-5 different donors ( Fig. 12A Furthermore, the effects of 1187 on T cell proliferation and TNF-α production were significantly stronger than those of the parental antibody (455), indicating that the application of antibody engineering to improve affinity led to the observed enhanced biological activities of antibody 1187 and its variants.

[0265] Example 8: Enhanced specific binding, Treg depletion, and blockade of CCL1-mediated chemotaxis compared to a benchmark anti-CCR8 antibody

[0266] Antibody 10A11 is an anti-CCR8 antibody produced by Shionogi Inc. Binding (Figure 3), Treg depletion (Figure 7), and TNF-α induction ( Fig.12F) showed that the lead candidate 1187 had better binding specificity and stronger Treg depletion and TNF-α induction capabilities compared to the 10A11 antibody. Figure 6C A side-by-side comparison was also performed between 1187 and 10A11 in the blocking assay shown in . 1187 in Fab form (no avidity) was much more potent in blocking CCL1-mediated chemotaxis than 10A11 in intact IgG form (with avidity).

[0267] Antibody TPP23411 is an anti-CCR8 antibody produced by Bayer. Side-by-side comparison of binding to hCCR8-transfected P815 cells and irrelevant GFP-transfected HEK293 cells showed that lead candidate 1187 had higher binding strength, affinity, and much lower non-specific binding than antibody 23411 ( Figure 2C -D).

[0268] Antibodies B16 and K17 are two anti-CCR8 antibodies produced by Jounce Therapeutics. Antibody Ab2-1 is an anti-CCR8 antibody produced by Surface Oncology. Antibody 4A19 is an anti-CCR8 antibody produced by BMS. Figure 4 ) and inhibition of CCL1-mediated chemotaxis ( Fig. 6E ) showed that lead candidate 1187 had the lowest polyreactivity and the highest potency in blocking CCL1-mediated chemotaxis. Cross-blocking assay ( Figure 5 ) also showed that the lead candidate 1187 shared the same binding epitope with 4A19 but not with other benchmark antibodies. The binding epitopes that 1187 and 4A19 had that were different from those of other benchmark antibodies correlated with their ability to block CCL1-mediated chemotaxis.

[0269] Example 9: In vivo efficacy in various murine models

[0270] The main mechanism of action provided for the anti-CCR8 antibodies described herein in cancer is the depletion of intratumoral Tregs to prevent immunosuppression and thus improve the anti-tumor activity of effector T cells. Since the lead candidate 1187 does not cross-react with murine CCR8, the potential for in vivo Treg depletion efficacy was tested in mice reconstructed with human CD34+ stem cells. Human CD34+ stem cells (Champion Ocology) were transplanted into immunodeficient NSG mice from Jackson Laboratories, which led to the development of a variety of human immune cells (Verma and Wesa, Curr Protoc Pharmacol. 2020Jun; 89 (1): e77.doi: 10.1002 / cpph.77). Mice were then injected with IL-15 plasmids to increase NK cell reconstruction, and then subcutaneously implanted with MDA-MB-232 human breast cancer cells to simulate tumor development. When the tumor size reached 100mm 3 At 4 hr, mice were treated twice weekly with vehicle, 10 mg / kg lead candidate 1187, or 10 mg / kg 1187+2FF. When the mean tumor size reached 2000 mm 3 At 4 pm, mice were euthanized. Splenocytes and digested tumor cells were resuspended and stained with anti-hCD45, anti-hCD3, anti-hCD56, anti-hCD4, anti-hCD8, anti-hFoxp3, and anti-hCD25 antibodies. The number of CD4+CD25+Foxp3+Treg, CD56+NK cells, and CD8+T cells were counted by flow cytometry. Both antibodies 1187 and 1187+2FF significantly reduced the number of regulatory T cells in the spleen and tumor ( Fig.13A -B). Overall, the reduction in Tregs was more severe in tumors than in the spleen, which is consistent with the expectation of higher CCR8 expression on tumor-infiltrating Tregs. Antibody 1187+2FF reduced the percentage of regulatory T cells in tumors by 20-fold, while unmodified 1187 reduced the percentage of Tregs by 4.6-fold. Therefore, the anti-CCR8 antibody 1187 preferentially reduced the number of regulatory T cells in tumors, and afucosylation (1187+2FF) enhanced this effect. In addition, antibody 1187+2FF also increased NK cells in tumors but not in the spleen ( Fig. 13C ) and CD8+ T cells ( Fig.13D), indicating that reducing the number of regulatory T cells with anti-CCR8 antibody treatment specifically enhances the infiltration of NK cells and CD8+ T cells within the tumor. 1187 and 1187+2FF reduce Tregs in the spleen and tumors, which may enhance systemic immune activity. Cytokine levels in serum samples collected from treated mice were assessed using Legendplex bead arrays (Biolegend). IP10, an IFN-γ responsive cytokine, was significantly increased by 1187+2FF treatment ( Fig.13E ), while other inflammatory cytokines (including IL6, TNF-α) remained unchanged, indicating that the antibody treatment did not induce a systemic inflammatory response.

[0271] Due to the lack of cross-reactivity to mouse CCR8, the antitumor activity of 1187+2FF was evaluated in hCCR8 knock-in mice (Biocytogen). In this mouse strain, the mouse CCR8 gene is replaced by hCCR8. Antibody 1187 binds to the knock-in version of hCCR8 expressed on activated mouse Tregs. MC38 tumor cells were implanted into hCCR8 knock-in mice. When tumors reached approximately 100 mm in size, the 3 At 4 , mice were treated with vehicle or 1187 + 2FF (10 mg / kg) twice a week for 4 weeks. When the average tumor size in the vehicle group reached 2000 mm 3 At 4 pm, mice were euthanized and tumor-infiltrating cells were analyzed by flow cytometry. 1187+2FF treatment inhibited tumor growth by 50% ( Fig.14A -C). In addition, the treatment also reduced the percentage of CD4+Foxp3+ in CD3+T cells and increased the ratio of CD8+ / Treg cells in the tumor ( Fig.14D ).

[0272] Anti-PD1 antibodies have shown impressive clinical benefits in cancer patients. However, many patients remain unresponsive to anti-PD1 treatment. To test whether depletion of CCR8+Tregs can enhance the tumor suppressive effect of anti-PD1 antibodies, PSB114 (1187+2FF) was combined with anti-mPD1 antibodies to treat hCCR8 knock-in mice with MC38 tumors. When the tumor size reached approximately 100 mm 3 Mice were treated twice a week with vehicle or 1187+2FF (10 mg / kg) or anti-mouse PD1 antibody (2 mg / kg RMP1-14, Biox cell) or anti-mouse PD1 antibody (2 mg / kg) plus PSB114 (10 mg / kg) for 4 weeks. Both PSB114 alone and anti-mouse PD1 antibody alone significantly delayed tumor growth. When anti-mouse PD1 antibody and PSB114 were combined, tumor inhibition was more significant ( Fig.15A -B). In the anti-mouse PD1 treatment group, 2 out of 8 mice had tumors less than 100 mm in size 3 In the anti-mPD1 antibody plus PSB114 combination group, 4 out of 8 mice had tumors less than 100 mm in size. 3 . In addition, when the two mice with complete tumor regression in the combination group were challenged with MC38 tumor implantation again 30 days later, both rejected the tumor, indicating the establishment of a durable anti-tumor memory response. To analyze tumor-infiltrating lymphocytes, tumors were collected from the vehicle or PSB114 treatment groups on day 29 and from the anti-PD1 antibody and combination groups on day 42. In both the PSB114 group alone and the PSB114 + anti-mPD1 antibody combination group, PSB114 significantly reduced CD4+Foxp3+Treg ( Fig.15F When combined with anti-mPD1 antibody, PSB114 also significantly increased the CD8 / Treg ratio ( Fig.15F ).

[0273] The B16F10 melanoma model is known to be resistant to anti-PD1 antibody treatment. Since PSB114 inhibits tumor growth by a different mechanism than anti-PD1 antibodies, we tested whether PSB114 could provide a different anti-tumor effect in the B16F10 model in hCCR8 knock-in mice. 3 When the average size of the mice was , the mice were randomly divided into groups and treated with vehicle or anti-mouse PD1 antibody (10 mg / kg) or PSB114 (10 mg / kg 1187+2FF). On day 15, PSB114 treatment alone significantly inhibited tumor growth by 50% (Figure 16), while anti-mPD1 antibody had no significant effect, indicating that PSB114 can be used to treat cancer patients who do not respond to anti-PD1 antibody treatment.

[0274] Example 10: Half-life and clearance

[0275] Polyreactivity or nonspecific binding of antibodies is associated with reduced half-life and increased clearance in vivo (Jain et al., Proc Natl Acad Sci US A. 2017 Jan 31; 114 (5): 944-949. doi: 10.1073 / pnas.1616408114). In vitro analysis showed that the lead 1187 candidate had low polyreactivity, as described above. The half-life of the 1187 lead candidate was examined in vivo using a human neonatal Fc receptor knock-in mouse model (B6.Cg-Fcgrttm1DcrTg (FCGRT) 32Dcr / DcrJ (Tg32, JAX item number 014565)). Human FcRn transgenic mice were given a single dose of 953, 1047 and 1187 + 2FF at a dose of 5 mg / kg. Control mice received a 5 mg / kg dose of FDA-approved drug rituximab, which has a known half-life. Blood samples obtained from mice between 5 minutes and 28 days after dosing were analyzed for circulating mAbs using an ELISA against human IgG. The half-life of antibody 1187+2FF was 13.65 days, comparable to 16 days for rituximab. The clearance of 1187+2FF in the circulation was 0.25 ml / hr / kg, comparable to 0.21 ml / hr / kg for rituximab.

[0276] Sequence Listing (using the Kabat numbering system):

[0277] No1:

[0278] DYTLDLSVTTVTDYYYPDIFSSPCDAELIQTNGK

[0279] No2:

[0280] MDYTLDLSVTTVTDYYYPDIFSSPCDAELIQTNGKLLLAVFYCLLFVFSLLGNSLVILVLVVCKKLRSITDVYLLNLALSDLLFVFSFPFQTYYLLDQWVFGTVMCKVVSGFYYIGFYSSMFFITLMSVDRYLAVVHAVYALKVRTIRMGTTLCLAVWLTAIMATIPLLVFYQVASE DGVLQCYSFYNQQTLKWKIFTNFKMNILGLLIPFTIFMFCYIKILHQLKRCQNHNKTKAIRLVLIVVIASLLFWVPFNVVLFLTSLHSMHILDGCSISQQLTYATHVTEIISFTHCCCVNPVIYAFVGEKFKKHLSEIFQKSCSQIFNYLGRQMPRESCEKSSSCQQHSSRSSSVDYIL<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0281] <h2 style=";text-align:left;direction:ltr"> No.3:<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0282] <h2 style=";text-align:left;direction:ltr"> EVQLVESGGGVVQPGRSLRLSCAASGFPFEPFAMNWVRQAPGKGLEWVARIRSKANNYATYYADSVKDRFAISRDNSKSTLYLLMHSLRFEDTAVYYCVRGRENRYGYAMDYWGQGTTVTVSS<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0283] <h2 style=";text-align:left;direction:ltr"> No.4:<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0284] <h2 style=";text-align:left;direction:ltr"> DVVMTQSPPSLPVTLGQSASISCRSSQSLLHSNGITYLYWFLQRPGQSPRLLIYRMSNLASGVPDRFSGSGSGTDFTLRISRVEAEDVGVYYCMQHLTYPFTFGIGTKVEIK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0285] <h2 style=";text-align:left;direction:ltr"> No.5:<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0286] <h2 style=";text-align:left;direction:ltr"> PFAMN<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0287] <h2 style=";text-align:left;direction:ltr"> No. 6:<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0288] <h2 style=";text-align:left;direction:ltr"> RIRSKANNYATYYADSVKD<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0289] <h2 style=";text-align:left;direction:ltr"> No.7:<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0290] <h2 style=";text-align:left;direction:ltr"> GRENRYGYAMDY<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0291] <h2 style=";text-align:left;direction:ltr"> No.8:<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0292] <h2 style=";text-align:left;direction:ltr"> RSSQSLLHSNGITYLY<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0293] <h2 style=";text-align:left;direction:ltr"> No.9:<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0294] <h2 style=";text-align:left;direction:ltr"> RMSNLAS<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0295] <h2 style=";text-align:left;direction:ltr"> No.10:<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0296] <h2 style=";text-align:left;direction:ltr"> MQHLTYPFT<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0297] <h2 style=";text-align:left;direction:ltr"> No.11:<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0298] GAGGTCCAACTCGTGGAGTCCGGCGGTGGCGTCGTACAGCCTGGGAGGTCACTTCGACTCTCTTGCGCTGCTTCTGGGTTTCCCTTTGAGCCTTTCGCTATGAACTGGGTACGCCAGGCCCCAGGTAAAGGTCTTGAATGGGTCGCCCGGATTCGCAGTAAGGCTAATAATTACGCCACATATTACGCCGATAGTGTGAAGGATCGGTTCGCTATCAGTAGGGACAACAGCAAAAGTACCCTTTACCTTCTTATGCATAGCCTCCGCTTTGAGGATACAGCAGTTTATTATTGTGTGCGAGGACGTGAGAATCGCTACGGTTACGCTATGGACTACTGGGGTCAAGGAACAACCGTGACTGTCTCTTCC

[0299] No12:

[0300] GACGTCGTCATGACTCAGTCCCCACCAAGTCTTCCTGTTACCCTTGGCCAGAGCGCATCAATTAGTTGTAGGAGCAGTCAGTCTCTCTTGCACTCTAACGGAATCACATACTTGTACTGGTTTCTGCAACGCCCTGGCCAATCACCACGGCTGCTTATTTATCGGATGTCCAATCTCGCCTCCGGCGTCCCCGACCGATTTTCCGGGTCCGGGAGTGGCACCGACTTCACCCTCCGAATCTCACGGGTGGAGGCTGAGGATGTCGGCGTCTACTACTGCATGCAGCATCTGACCTACCCATTTACATTCGGGATCGGAACTAAAGTCGAAATCAAA

[0301] No13:

[0302] EVQLVESGGGVVQPGRSLRLSCAASGFPFEPFAMNWVRQAPGKGLEWVARIRSKANNYATYYADSVKDRFAISRDNSKSTLYLLMHSLRFEDTAVYYCVRGRENNYGYAMDYWGQGTTVTVSS

[0303] No14:

[0304] DVVMTQSPPSLPVTLGQSASISCRSSQSLLHSNGITYLYWFLQRPGQSPRLLIYRMSNLASGVPDRFSGSGSGTDFTLRISRVEAEDVGVYYCMQHLTYPFTFGIGTKVEIK

[0305] No15:

[0306] PFAMN

[0307] No16:

[0308] RIRSKANNYATYYADSVKD

[0309] No17:

[0310] GRENNYGYAMDY

[0311] No18:

[0312] RSSQSLLHSNGITYLY

[0313] No19:

[0314] RMSNLAS

[0315] No20:

[0316] MQHLTYPFT

[0317] No21:

[0318] GAGGTCCAACTCGTGGAGTCCGGCGGTGGCGTCGTACAGCCTGGGAGGTCACTTCGACTCTCTTGCGCTGCTTCTGGGTTTCCCTTTGAGCCTTTCGCTATGAACTGGGTACGCCAGGCCCCAGGTAAAGGTCTTGAATGGGTCGCCCGGATTCGCAGTAAGGCTAATAATTACGCCACATATTACGCCGATAGTGTGAAGGATCGGTTCGCTATCAGTAGGGACAACAGCAAAAGTACCCTTTACCTTCTTATGCATAGCCTCCGCTTTGAGGATACAGCAGTTTATTATTGTGTGCGAGGACGTGAGAATAACTACGGTTACGCTATGGACTACTGGGGTCAAGGAACAACCGTGACTGTCTCTTCC

[0319] No22:

[0320] GACGTCGTCATGACTCAGTCCCCACCAAGTCTTCCTGTTACCCTTGGCCAGAGCGCATCAATTAGTTGTAGGAGCAGTCAGTCTCTCTTGCACTCTAACGGAATCACATACTTGTACTGGTTTCTGCAACGCCCTGGCCAATCACCACGGCTGCTTATTTATCGGATGTCCAATCTCGCCTCCGGCGTCCCCGACCGATTTTCCGGGTCCGGGAGTGGCACCGACTTCACCCTCCGAATCTCACGGGTGGAGGCTGAGGATGTCGGCGTCTACTACTGCATGCAGCATCTGACCTACCCATTTACATTCGGGATCGGAACTAAAGTCGAAATCAAA

[0321] No23:

[0322] EVQLVESGGGVVQPGRSLRLSCAASGFPFEPFAMNWVRQAPGKGLEWVARIRSKANNYATYYADSVKDRFAISRDNSKRTLYLLMHSLRFEDTAVYYCVRGRENNYGYAMDYWGQGTTVTVSS

[0323] No24:

[0324] DVVMTQSPPSLPVTLGQSASISCRSSQSLLHSNGITYLYWFLQRPGQSPRLLIYRMSNLASGVPDRFSGSGSGTDFTLRISRVEAEDVGVYYCMQHLTYPFTFGIGTKVEIK

[0325] No25:

[0326] PFAMN

[0327] No26:

[0328] RIRSKANNYATYYADSVKD

[0329] No27:

[0330] GRENNYGYAMDY

[0331] No28:

[0332] RSSQSLLHSNGITYLY

[0333] No29:

[0334] RMSNLAS

[0335] No30:

[0336] MQHLTYPFT

[0337] No31:

[0338] ATGGACATGAGAGTGCCCGCTCAGCTGCTGGGACTGCTGCTGTTGTGGTTGAGAGGCGCTAGATGCGAGGTGCAGCTGGTGGAATCTGGTGGCGGAGTTGTGCAGCCTGGCAGATCCCTGAGACTGTCTTGTGCCGCCTCTGGCTTCCCATTCGAGCCCTTCGCTATGAACTGGGTCCGACAGGCTCCTGGCAAAGGCCTGGAATGGGTCGCCCGGATCAGATCCAAGGCCAACAATTACGCCACCTACTACGCCGACTCCGTGAAGGACAGATTCGCCATCTCTCGGGACAACTCCAAGCGGACCCTGTACCTGCTGATGCACTCCCTGAGATTCGAGGACACCGCCGTGTACTACTGTGTGCGGGGCAGAGAGAACAACTACGGCTACGCCATGGACTACTGGGGCCAGGGCACAACAGTGACCGTGTCCTCT

[0339] No32:

[0340] ATGGACATGAGAGTGCCCGCTCAGCTGCTGGGACTGCTGCTGTTGTGGTTGAGAGGCGCCAGATGCGACGTGGTCATGACACAGTCTCCACCTAGCCTGCCTGTGACACTGGGCCAGTCTGCCTCCATCTCCTGCAGATCCTCTCAGTCCCTGCTGCACTCCAACGGCATTACCTACCTGTACTGGTTCCTGCAGCGGCCTGGCCAGTCTCCTAGACTGCTGATCTACCGGATGTCCAACCTGGCCTCTGGCGTGCCCGATAGATTTTCCGGCTCTGGCTCTGGCACCGACTTCACCCTGAGAATCTCCAGAGTGGAAGCCGAGGACGTGGGCGTGTACTACTGTATGCAGCACCTGACCTATCCTTTCACCTTCGGCATCGGCACCAAGGTGGAAATCAAG

[0341] No33:

[0342] EVQLVESGGGLVQPGGSLRLSCAASGFPFEPFAMNWVRQAPGKGLEWVGRIRSKANNYATYYADSVKDRFTISRDDSKRSLYLLMNSLKFEDTAVYYCVRGRENNYGYAMDYWGQGTTVTVSS

[0343] No34:

[0344] DVVMTQSPLSLPVTLGQPASISCRSSQSLLHSNGITYLYWFQQRPGQSPRRLIYRMSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQHLTYPFTFGIGTKVEIK

[0345] No35:

[0346] PFAMN

[0347] No36:

[0348] RIRSKANNYATYYADSVKD

[0349] No37:

[0350] GRENNYGYAMDY

[0351] No38:

[0352] RSSQSLLHSNGITYLY

[0353] No39:

[0354] RMSNLAS

[0355] No40:

[0356] MQHLTYPFT

[0357] No41:

[0358] GAAGTGCAGCTTGTTGAATCTGGAGGGGGTCTGGTCCAGCCAGGTGGGTCCCTGCGTTTGTCCTGTGCTGCTTCAGGTTTTCCTTTTGAACCTTTCGCTATGAATTGGGTTAGGCAGGCCCCCGGTAAGGGTCTTGAATGGGTGGGTCGAATACGGTCCAAGGCCAACAATTACGCCACATATTACGCAGATAGCGTGAAAGATCGGTTCACCATAAGTCGAGACGACTCCAAAAGGAGCCTTTATCTTCTTATGAACAGTCTCAAGTTTGAAGACACAGCAGTCTATTACTGTGTCCGTGGTAGAGAAAACAATTACGGATATGCAATGGACTACTGGGGGCAAGGCACAACCGTGACTGTCTCTTCC

[0359] No42:

[0360] GATGTTGTTATGACACAGAGTCCTCTGTCACTGCCAGTTACCCTTGGACAGCCCGCATCCATCAGTTGCCGGAGCAGTCAGTCCTTGTTGCATTCAAACGGAATTACCTATCTGTACTGGTTCCAGCAGCGACCCGGCCAATCTCCCAGACGCCTCATATATCGGATGAGCAATCTGGCATCAGGGGTACCTGACAGATTTTCCGGGAGCGGGTCTGGCACAGATTTTACACTCAAAATTTCTCGTGTGGAGGCAGAGGACGTTGGAGTTTATTACTGTATGCAACATCTGACTTACCCATTCACCTTTGGGATAGGAACTAAAGTCGAAATCAAA

[0361] No.43:

[0362] ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0363] No.44:

[0364] RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKAYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Claims

1. An anti-CC motif chemokine receptor 8 (anti-CCR8) monoclonal antibody (Mab) comprising a heavy chain variable domain (V H ) V of complementarity determining region 1 (CDR1), CDR2 and CDR3 H and light chain variable domain (V L )V of CDR1, CDR2 and CDR3 L , Among them, anti-CCR8 Mab 953 antibody V H CDR1, CDR2 and CDR3 have the amino acid sequences of SEQ ID NOs: 5, 6 and 7, respectively, and Mab 953 antibody V L CDR1, CDR2, and CDR3 have the amino acid sequences of SEQ ID NOs: 8, 9, and 10, respectively; Among them, anti-CCR8 Mab 1047 antibody V H CDR1, CDR2 and CDR3 have the amino acid sequences of SEQ ID NOs: 15, 16 and 17, respectively, and the Mab 1047 antibody V L CDR1, CDR2, and CDR3 have the amino acid sequences of SEQ ID NOs: 18, 19, and 20, respectively; Among them, anti-CCR8 Mab 1187 antibody V H CDR1, CDR2 and CDR3 have the amino acid sequences of SEQ ID NOs: 25, 26 and 27, respectively, and the Mab 1187 antibody V L CDR1, CDR2, and CDR3 have the amino acid sequences of SEQ ID NOs: 28, 29, and 30, respectively; Among them, anti-CCR8 Mab 1434 antibody V H CDR1, CDR2 and CDR3 have the amino acid sequences of SEQ ID NOs: 35, 36 and 37, respectively, and the Mab 1434 antibody V L CDR1, CDR2, and CDR3 have the amino acid sequences of SEQ ID NOs: 38, 39, and 40, respectively; and in: (a) The equilibrium dissociation constant (K) of the anti-CCR8 antibody binding to the amino-terminal extracellular domain of CCR8 D ) does not exceed 1 nM; (b) K binding to the amino-terminal extracellular domain of CCR8 A At least 1×10 -6 , and / or (c) ICs that block CCL1-mediated chemotaxis in P815 cells stably transfected with full-length human CCR8 protein 50 Less than 100ng / ml.

2. The anti-CCR8 antibody according to claim 1, wherein the anti-CCR8 antibody blocks the IC of CCL1-mediated chemotaxis in P815 cells stably transfected with full-length human CCR8 protein. 50 Less than 50ng / ml.

3. The anti-CCR8 antibody according to claim 1-2, wherein the anti-CCR8 antibody binds to the amino-terminal extracellular domain of CCR8. D Not more than 0.8nM.

4. The anti-CCR8 antibody according to claims 1-3, wherein the anti-CCR8 antibody binds to the amino-terminal extracellular domain of CCR8. A At least 1.8×10 -6 .

5. The anti-CCR8 antibody according to claims 1-4, wherein the anti-CCR8 antibody binds to the amino-terminal extracellular domain of CCR8. D Not more than 0.7nM.

6. The anti-CCR8 antibody according to claims 1-5, wherein: (1) V of the anti-CCR8 Mab 953 antibody H comprising an amino acid sequence encoded by a polynucleotide encoding SEQ ID NO: 11, and the V L comprising an amino acid sequence encoded by a polynucleotide encoding SEQ ID NO: 12; (2) V of the anti-CCR8 Mab 1047 antibody H comprising an amino acid sequence encoded by a polynucleotide encoding SEQ ID NO: 21, and the V L comprising an amino acid sequence encoded by a polynucleotide encoding SEQ ID NO: 22; (3) V of the anti-CCR8 Mab 1187 antibody H comprising an amino acid sequence encoded by a polynucleotide encoding SEQ ID NO: 31, and the V L comprising an amino acid sequence encoded by a polynucleotide encoding SEQ ID NO: 32; and (4) V of the anti-CCR8 Mab 1434 antibody H comprising an amino acid sequence encoded by a polynucleotide encoding SEQ ID NO: 41, and the V L Comprising an amino acid sequence encoded by a polynucleotide encoding SEQ ID NO:

42.

7. The anti-CCR8 antibody according to claims 1-6, wherein: (1) V of the anti-CCR8 Mab 953 antibody H comprising the amino acid sequence of SEQ ID NO: 3, and the V L An amino acid sequence comprising SEQ ID NO: 4; (2) V of the anti-CCR8 Mab 1047 antibody H comprising the amino acid sequence of SEQ ID NO: 13, and the V L An amino acid sequence comprising SEQ ID NO: 14; (3) V of the anti-CCR8 Mab 1187 antibody H comprising the amino acid sequence of SEQ ID NO: 23, and the V L comprising the amino acid sequence of SEQ ID NO: 24; and (4) V of the anti-CCR8 Mab 1434 antibody H comprising the amino acid sequence of SEQ ID NO: 33, and the V L Comprising the amino acid sequence of SEQ ID NO:

34.

8. The anti-CCR8 antibody according to claims 1-7, wherein the anti-CCR8 antibody is a human or humanized IgG antibody.

9. The anti-CCR8 antibody according to claims 1-8, wherein the anti-CCR8 antibody is an IgG1 or IgG3 antibody.

10. The anti-CCR8 antibody according to claims 1-8, wherein the anti-CCR8 antibody is an IgG2 or IgG4 antibody.

11. The anti-CCR8 antibody according to claims 1-9, wherein the anti-CCR8 antibody is an IgG1 antibody.

12. The anti-CCR8 antibody according to claims 1-11, wherein the anti-CCR8 antibody does not comprise a second heavy chain constant domain (C H 2) and does not contain the third heavy chain constant domain (C H 3).

13. A mixture or bispecific antibody, (a) wherein the mixture or bispecific antibody is a mixture, and the mixture comprises the anti-CCR8 antibody according to claims 1-12 and a second antibody or a targeted inhibitor, wherein: (i) the second antibody is PSB205 MabPair, or binds to an antigen selected from the group consisting of programmed cell death protein 1 ligand 1 (PDL1), programmed cell death protein 1 ligand 2 (PDL2), programmed cell death protein 1 (PD1), cytotoxic T lymphocyte-associated protein 4 (CTLA4), CD20, cancer antigens, colony stimulating factor 1 receptor (CSF-1R), and viral antigens, or (ii) the second antibody is an agonist antibody that binds to CD27, CD40, tumor necrosis factor receptor superfamily member 4 (OX40), glucocorticoid-induced TNFR-related gene (GITR), or tumor necrosis factor receptor superfamily member 9 (4-1BB); or (2) the targeted inhibitor targets an interaction involving a protein, wherein the protein is selected from the group consisting of PDL1, PDL2, PD1, CTLA4, TREM2, FOLR2, LILRB1, LILRB2, MIC-A and MIC-B, cancer antigens, CSF-1R and viral antigens; or (b) wherein the mixture or bispecific antibody is a bispecific antibody and the bispecific antibody comprises the anti-CCR8 antibody according to claim 1 and another antibody, wherein: (1) the other antibody binds to an antigen selected from the group consisting of PDL1, PDL2, PD1, CTLA4, CD20, TREM2, FOLR2, LILRB1, LILRB2, MIC-A and MIC-B, cancer antigens, CSF-1R and viral antigens, or (2) The other antibody is an agonistic antibody that binds to CD27, CD40, OX40, GITR or 4-1BB.

14. The mixture or bispecific antibody according to claim 13, wherein the cancer antigen is selected from the group consisting of HER2, EGFR, SLAMF-7, Claudin 18.2, CD20, CD33, CD38, CD123 and B7H4.

15. The mixture or bispecific antibody according to claims 13-14, The mixture is an antibody mixture comprising the anti-CCR8 antibody according to claims 1 to 12, and the second antibody of the mixture or the other antibody of the bispecific antibody is an anti-cancer antigen antibody.

16. The mixture or bispecific antibody according to claims 13-15, wherein: (a) the mixture or bispecific antibody is a mixture, and the second antibody of the mixture is an anti-PD1 antibody, wherein the second antibody inhibits the interaction between human PD1 (hPD1) and human PDL1 (hPDL1); or (b) wherein the mixture or bispecific antibody is a bispecific antibody, and the other antibody of the bispecific antibody is an anti-PD1 antibody, wherein the other antibody inhibits the interaction of hPD1 and hPDL1.

17. The mixture or bispecific antibody according to claims 13-16, wherein the second antibody binds to an antigen selected from the group consisting of programmed cell death protein 1 ligand 1 (PDL1), programmed cell death protein 1 ligand 2 (PDL2), programmed cell death protein 1 (PD1), cytotoxic T lymphocyte-associated protein 4 (CTLA4), CD20, cancer antigens, colony stimulating factor 1 receptor (CSF-1R) and viral antigens, or (ii) the second antibody is an agonist antibody that binds to CD27, CD40, tumor necrosis factor receptor superfamily member 4 (OX40), glucocorticoid-induced TNFR-related gene (GITR) or tumor necrosis factor receptor superfamily member 9 (4-1BB).

18. The mixture or bispecific antibody according to claims 13-15, (a) wherein the mixture or bispecific antibody is a mixture, and the second antibody of the mixture is an anti-CTLA4 antibody, wherein the second antibody inhibits the interaction of human CTLA4 (hCTLA4) with human B lymphocyte activation antigen B7-1 (hB7-1) and / or human B lymphocyte activation antigen B7-2 (hB7-2); or (b) wherein the mixture or bispecific antibody is a bispecific antibody and the other antibody of the bispecific antibody is an anti-CTLA4 antibody, wherein the other antibody inhibits the interaction of hCTLA4 with hB7-1 and / or hB7-2.

19. The mixture or bispecific antibody according to claim 15, wherein the second antibody of the mixture or the other antibody of the bispecific antibody is an anti-cancer antigen antibody.

20. The mixture or bispecific antibody of claims 13-19, wherein the cancer antigen is selected from the group consisting of epidermal growth factor receptor (EGFR), V-ERB-B2 avian erythroblastic leukemia viral oncogene homolog 2 (HER2), epithelial cell adhesion molecule (EpCAM), glypican 3 (GPC3), tumor necrosis factor receptor superfamily member 17 (TMFRSF17, referred to herein as BCMA), CD20, claudin-18.2, and prostate specific antigen (PSA).

21. The mixture or bispecific antibody according to claims 13-20, wherein the second antibody of the mixture or the other antibody of the bispecific antibody is an anti-claudin-18.2 antibody, an anti-CD20 antibody, an anti-HER2 antibody or the PSB205 MabPair.

22. The mixture or bispecific antibody according to claims 13-21, which is a bispecific antibody, wherein the bispecific antibody is an IgG antibody.

23. One or more polynucleotides encoding the anti-CCR8 antibody according to claims 1-12.

24. One or more vectors comprising one or more polynucleotides according to claim 23.

25. The one or more vectors of claim 24 which are viral vectors.

26. One or more polynucleotides encoding the mixture or bispecific antibody according to claims 13-22.

27. One or more vectors comprising one or more polynucleotides according to claim 26.

28. The one or more vectors of claim 27 which are viral vectors.

29. A host cell comprising one or more polynucleotides according to claims 23 and 26 or one or more vectors according to claims 24-25 and 27-28.

30. The host cell according to claim 29, which is a mammalian cell. The host cell according to claim 30 , which is a CHO cell or a mouse myeloma cell.

32. A method for preparing an anti-CCR8 antibody, comprising the following steps: (a) introducing one or more polynucleotides according to claims 23-29 into a host cell; (b) culturing the host cell in a culture medium; and (c) recovering the anti-CCR8 antibody from the culture medium or the host cell pellet.

33. The method of claim 32, wherein The anti-CCR8 antibody is a human, humanized or chimeric IgG antibody.

34. A method of treating a cancer patient comprising administering to the patient an anti-CCR8 antibody according to claims 1-12.

35. A method of treating a cancer patient comprising administering to the patient a mixture or a bispecific antibody according to claims 13-22.

36. The method of claims 34-35, wherein the antibody is administered by injection into a tumor.

37. The method of claims 34-36, wherein the mixture or bispecific antibody is administered by injection into a tumor.

38. The method of claims 34-37, wherein the anti-CCR8 antibody is administered parenterally.

39. The method of claims 34-38, wherein the mixture or bispecific antibody is administered by injection into a tumor.

40. A method of treating a cancer patient, comprising: (a) administering to the patient a bispecific antibody comprising (1) an anti-CCR8 antibody according to claims 1-12, and (2) an antibody that binds to claudin 18.2, CD20, PDL1, PDL2, PD1, HER2, EGFR, CTLA4, GITR, leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1), LILRB2, LILRB3, LILRB4, LILRB5, CD24, MICA or MICB, or an agonistic antibody that binds to CD27, CD40, OX40, GITR or 4-1BB; (b) administering to the patient one or more polynucleotides or vectors encoding the bispecific antibody of (a); (c) administering (1) to the patient An anti-CCR8 antibody according to claim 1 and (2) one or more of the following additional antibodies: PSB205 MabPair, or antibodies that bind to claudin 18.2, CD20, PDL1, PDL2, PD1, HER2, EGFR, CTLA4, GITR, leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1), LILRB2, LILRB3, LILRB4, LILRB5, CD24, MICA, MICB, or agonistic antibodies that bind to CD27, CD40, OX40, GITR or 4-1BB; or (d) administering to the patient one or more polynucleotides or vectors encoding the antibody of (c); Wherein (c) the anti-CCR8 antibody of (1) or one or more polynucleotides or vectors encoding the same is administered to the patient before, after or simultaneously with (c) the one or more additional antibodies of (2) or one or more polynucleotides or vectors encoding the additional antibodies.

41. The method of claims 34-40, wherein the patient is treated with a chemotherapeutic agent, radiation, or a STING agonist prior to, after, or concurrently with administration of the anti-CCR8 antibody.

42. The method of claims 34-41, wherein the STING agonist is selected from the group consisting of ADU-S100, MK-1454, E7766, BMS-986301, IMSA101, SB 11285, and SNY1891.

43. The method of claims 34-42, wherein the patient is treated with a chemotherapeutic agent, radiation, or a STING agonist prior to, after, or simultaneously with administration of the mixture or bispecific antibody.

44. The method of claim 43, wherein the STING agonist is selected from the group consisting of ADU-S100, MK-1454, E7766, BMS-986301, IMSA101, SB 11285, and SNY1891.

45. The method of claims 34-44, wherein the cancer is selected from the group consisting of Hodgkin's lymphoma, non-Hodgkin's lymphoma, Kaposi's sarcoma, T-cell leukemia and lymphoma, melanoma, breast cancer, renal cell carcinoma, head and neck cancer, anal cancer, laryngeal cancer, oral cancer, liver cancer, cervical cancer, stomach cancer, penis cancer, vaginal cancer, vulvar cancer, lung cancer, colon cancer, leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, lymphoma, esophageal cancer, hepatocellular carcinoma, pancreatic adenocarcinoma, pancreatic ductal adenocarcinoma, ovarian cancer, head and neck cancer, glioma, glioblastoma, squamous cell carcinoma, renal cell carcinoma, prostate cancer, and bladder cancer.

46. ​​The method of any one of claims 34-45, wherein the cancer is selected from the group consisting of Hodgkin's lymphoma, non-Hodgkin's lymphoma, Kaposi's sarcoma, T-cell leukemia and lymphoma, melanoma, breast cancer, renal cell carcinoma, head and neck cancer, anal cancer, laryngeal cancer, oral cancer, liver cancer, cervical cancer, stomach cancer, penis cancer, vaginal cancer, vulvar cancer, lung cancer, colon cancer, leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, lymphoma, esophageal cancer, hepatocellular carcinoma, pancreatic adenocarcinoma, pancreatic ductal adenocarcinoma, ovarian cancer, head and neck cancer, glioma, glioblastoma, squamous cell carcinoma, renal cell carcinoma, prostate cancer, and bladder cancer.

Citation Information

Cited By

  • Purification method of monoclonal antibody

    CN119264256A

  • A method for purifying a monoclonal antibody

    CN119264256B